KR102557702B1 - Composition for anti-inflammation comprising Aronia vinegar - Google Patents
Composition for anti-inflammation comprising Aronia vinegar Download PDFInfo
- Publication number
- KR102557702B1 KR102557702B1 KR1020210002222A KR20210002222A KR102557702B1 KR 102557702 B1 KR102557702 B1 KR 102557702B1 KR 1020210002222 A KR1020210002222 A KR 1020210002222A KR 20210002222 A KR20210002222 A KR 20210002222A KR 102557702 B1 KR102557702 B1 KR 102557702B1
- Authority
- KR
- South Korea
- Prior art keywords
- aronia
- alcohol
- lysate
- fermentation
- yeast
- Prior art date
Links
- 241001444063 Aronia Species 0.000 title claims abstract description 240
- 239000000052 vinegar Substances 0.000 title claims abstract description 58
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 271
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 207
- 238000000855 fermentation Methods 0.000 claims abstract description 200
- 230000004151 fermentation Effects 0.000 claims abstract description 199
- 235000014443 Pyrus communis Nutrition 0.000 claims abstract description 74
- 239000012141 concentrate Substances 0.000 claims abstract description 70
- 239000000284 extract Substances 0.000 claims abstract description 40
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 133
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 125
- 239000006166 lysate Substances 0.000 claims description 108
- 239000000047 product Substances 0.000 claims description 39
- 235000014101 wine Nutrition 0.000 claims description 29
- 239000006228 supernatant Substances 0.000 claims description 11
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 26
- 210000002540 macrophage Anatomy 0.000 abstract description 15
- 238000002156 mixing Methods 0.000 abstract description 11
- 230000001476 alcoholic effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 8
- 238000005119 centrifugation Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 4
- 231100000065 noncytotoxic Toxicity 0.000 abstract description 2
- 230000002020 noncytotoxic effect Effects 0.000 abstract description 2
- 235000000346 sugar Nutrition 0.000 description 88
- 229960000583 acetic acid Drugs 0.000 description 86
- 235000008504 concentrate Nutrition 0.000 description 65
- 238000000605 extraction Methods 0.000 description 50
- 239000002609 medium Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 32
- 241001123226 Kazachstania servazzii Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- 230000008859 change Effects 0.000 description 28
- 238000005259 measurement Methods 0.000 description 23
- 229920002498 Beta-glucan Polymers 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 17
- 230000032683 aging Effects 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 239000006227 byproduct Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 235000013399 edible fruits Nutrition 0.000 description 12
- 230000028709 inflammatory response Effects 0.000 description 12
- 239000004410 anthocyanin Substances 0.000 description 11
- 235000010208 anthocyanin Nutrition 0.000 description 11
- 229930002877 anthocyanin Natural products 0.000 description 11
- 150000004636 anthocyanins Chemical class 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- -1 patches Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 4
- 229920000310 Alpha glucan Polymers 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 244000283763 Acetobacter aceti Species 0.000 description 3
- 235000007847 Acetobacter aceti Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000010421 standard material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 241000589220 Acetobacter Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 101150008905 baf-1 gene Proteins 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 1
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 240000005662 Aronia melanocarpa Species 0.000 description 1
- 235000007425 Aronia melanocarpa Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 101001120428 Lithospermum erythrorhizon Phenylalanine ammonia-lyase 2 Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000019226 kombucha tea Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12J—VINEGAR; PREPARATION OR PURIFICATION THEREOF
- C12J1/00—Vinegar; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 아로니아 식초를 포함하는 항염증용 조성물에 관한 것으로서, 보다 구체적으로는 아로니아 분쇄물의 주정 추출물과 배 농축액을 혼합한 후 알코올 발효 및 초산 발효하고 원심분리하여 제조된 아로니아 식초를 함유하는 항염증용 조성물, 특히 염증의 예방 및/또는 개선을 위한 식품 조성물에 관한 것이다. 본 발명에 따른 아로니아 식초는 대식세포에서 NO 활성을 억제하고 IL-6의 생성을 억제하므로 염증의 예방, 개선, 및 치료를 위한 약학 및 식품 조성물로서 유용하다. 더욱이 본 발명에 따른 아로니아 식초는 세포독성이 없고 천연 아로니아로부터 유래한 물질이므로 안전하게 사용 가능하다.The present invention relates to an anti-inflammatory composition containing aronia vinegar, and more specifically, contains aronia vinegar prepared by mixing alcohol extract and pear concentrate of pulverized aronia, followed by alcoholic fermentation and acetic acid fermentation, followed by centrifugation. It relates to an anti-inflammatory composition, particularly a food composition for preventing and/or improving inflammation. Aronia vinegar according to the present invention inhibits NO activity in macrophages and inhibits the production of IL-6, so it is useful as a pharmaceutical and food composition for preventing, improving, and treating inflammation. Moreover, the aronia vinegar according to the present invention is non-cytotoxic and can be safely used because it is a material derived from natural aronia.
Description
본 발명은 아로니아 식초를 포함하는 항염증용 조성물에 관한 것으로서, 보다 구체적으로는 아로니아 분쇄물의 주정 추출물과 배 농축액을 혼합한 후 알코올 발효 및 초산 발효하고 원심분리하여 제조된 아로니아 식초를 함유하는 항염증용 조성물, 특히 염증의 예방 및/또는 개선을 위한 식품 조성물에 관한 것이다.The present invention relates to an anti-inflammatory composition containing aronia vinegar, and more specifically, contains aronia vinegar prepared by mixing alcohol extract and pear concentrate of pulverized aronia, followed by alcoholic fermentation and acetic acid fermentation, followed by centrifugation. It relates to an anti-inflammatory composition, particularly a food composition for preventing and/or improving inflammation.
염증이란 물리적, 화학적 자극이나 조직손상 세균감염과 같은 외부 자극에 대응하기 위한 생체조직에서 일어나는 방어 기전이다. 하지만 지속적인 염증반응은 오히려 혈관 활성물질인 히스타민(histamine), 프로스타글란딘(prostaglandins), 류코트리엔(leukotriene) 등에 의해 혈관 투과성이 증가되어 만성 염증을 유도하거나 점막 손상을 촉진시켜 통증, 부종, 발열 등 기능장애를 일으키며 염증성 질환을 비롯하여 다양한 질환을 유발한다. 체내의 염증반응에 관여하는 세포 중 하나인 대식세포는 식균작용을 통해 염증반응과 면역기능을 조절하는 세포로 항상성을 유지하는데 매우 중요한 역할을 한다. 대식세포는 그람 음성균의 외막성분인 LPS(lipoplolysaccharide)의 자극으로 인해 활성화되며 감염 초기에는 생체 방어에 중추적인 역할을 하지만, 과도한 LPS 자극에 의해 활성화된 대식세포는 염증성 사이토카인 증가로 유도된다. 대식세포에서 LPS에 의해 분비되는 전염증성 사이토카인(pro-inflammatory cytokine) 중 IL-6는 B 세포를 형질세포로 분화시켜 항체 생산을 촉진하여 급성 염증 반응을 만성 단계로 전환시킨다(Kang BK. et.al., Microbiol. Biotechnol. Lett., 44:236-245, 2016). 또한 TNF-α는 전신성 염증에 관여하는 사이토카인으로, 과량 생산시 발열, 세포사멸을 유도하며, IL-1β는 활성화된 대식세포에서 염증반응의 주요 매개체로 작용한다(Kim JH. et.al., The Korean Society of Food Preservation, 24:1149-1157, 2018).Inflammation is a defense mechanism that occurs in biological tissues to respond to external stimuli such as physical and chemical stimuli or tissue damage and bacterial infection. However, the continuous inflammatory response rather increases vascular permeability by vasoactive substances such as histamine, prostaglandins, and leukotriene, which induces chronic inflammation or promotes mucosal damage, resulting in functional disorders such as pain, edema, and fever. It causes a variety of diseases, including inflammatory diseases. Macrophages, one of the cells involved in the inflammatory response in the body, play a very important role in maintaining homeostasis as cells that regulate inflammatory responses and immune functions through phagocytosis. Macrophages are activated by stimulation of LPS (lipopolysaccharide), a component of the outer membrane of Gram-negative bacteria, and play a pivotal role in biological defense in the early stage of infection. However, macrophages activated by excessive LPS stimulation are induced to increase inflammatory cytokines. Among the pro-inflammatory cytokines secreted by LPS in macrophages, IL-6 converts an acute inflammatory response into a chronic phase by differentiating B cells into plasma cells and promoting antibody production (Kang BK. et al. al., Microbiol. Biotechnol. Lett., 44:236-245, 2016). In addition, TNF-α is a cytokine involved in systemic inflammation, and excessive production induces fever and apoptosis, and IL-1β acts as a major mediator of inflammatory responses in activated macrophages (Kim JH. et.al. , The Korean Society of Food Preservation, 24:1149-1157, 2018).
또한 체내의 염증 과정에는 iNOS(inducible nitric oxide synthase) 및 COX-2(cyclooxygenase-2)에 의하여 과량의 NO(nitric oxide) 및 PEG2(prostaglandin E2) 등의 염증 인자가 생성된다. NO는 반응성이 높은 물질로 NOS(NO synthase)에 의해 L-아르기닌(L-arginine)으로부터 생성되며, 외부자극이나 전염증성 사이토카인 등에 의해 자극을 받게 되면 다량의 NO를 생산한다. 과잉 생산된 NO는 혈관 투과성 및 부종 등의 염증 반응을 촉진한다고 보고되고 있다. 또 다른 주요 염증 매개 인자인 COX는 세포막의 인지질로부터 아라키돈산(arachidonic acid)이 유리된 후 프로스타글란딘으로의 변화를 촉진시키는 효소이며, COX-2는 성장 인자(growth factors), 사이토카인 및 LPS 등 다양한 자극에 의해서 대식세포(macrophage)나 단핵구(monocyte) 등의 세포에서 다량 발현된다. 이로 인해 발생된 프로스타글란딘은 종양의 세포사멸을 억제하고 혈관 생성을 유도하여 종양 생성에 관여한다. 따라서 염증 질환 및 예방 조성물로서 대식세포 매개 염증 반응의 조절을 위한 NO 생성 효소인 iNOS, 프로스타글란딘 생합성의 단계 효소인 COX-2와 염증성 사이토카인들의 발현 조절과 이들의 주요 신호전달 분자인 MAPKs와 NF-κB의 발현을 조절할 수 있는 물질이 염증 예방 및 개선 조성물로서 주목을 받고 있다. 특히, 천연물에 의한 염증 예방 및 개선 조성물에 대한 연구가 활발히 진행되고 있다(Kim SY. et. al., J. Korean Orient. Med. Ophthalmol. Otolaryngol. Dermatol., 26:54-64, 2013).In the inflammatory process in the body, inflammatory factors such as excessive nitric oxide (NO) and prostaglandin E2 (PEG2) are produced by inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). NO is a highly reactive substance and is produced from L-arginine by NO synthase (NOS), and when stimulated by external stimuli or pro-inflammatory cytokines, a large amount of NO is produced. It has been reported that overproduced NO promotes inflammatory responses such as vascular permeability and edema. COX, another major inflammatory mediator, is an enzyme that promotes the conversion of arachidonic acid to prostaglandin after the release of arachidonic acid from phospholipids in cell membranes. It is expressed in large amounts in cells such as macrophages and monocytes by stimulation. The resulting prostaglandin suppresses tumor apoptosis and induces angiogenesis to be involved in tumor formation. Therefore, as a composition for preventing inflammatory diseases and macrophage-mediated inflammatory responses, NO-generating enzyme iNOS, prostaglandin biosynthesis step enzyme COX-2, and expression control of inflammatory cytokines and their major signaling molecules, MAPKs and NF- Substances capable of regulating the expression of κB are attracting attention as compositions for preventing and improving inflammation. In particular, studies on compositions for preventing and improving inflammation by natural products are being actively conducted (Kim SY. et. al., J. Korean Orient. Med. Ophthalmol. Otolaryngol. Dermatol., 26:54-64, 2013).
이에 본 발명자들은 아로니아(Aronia melanocarpa)에 대하여 다양한 연구를 수행하던 중, 아로니아 식초가 항염증 효과가 매우 우수함을 확인하고 본 발명을 완성하게 되었다.Accordingly, while the present inventors were conducting various studies on Aronia (Aronia melanocarpa), it was confirmed that Aronia vinegar had a very excellent anti-inflammatory effect and completed the present invention.
본 발명의 하나의 목적은 아로니아 식초를 유효성분으로 포함하는 항염증용 조성물을 제공하는 것이다.One object of the present invention is to provide an anti-inflammatory composition comprising aronia vinegar as an active ingredient.
본 발명의 다른 하나의 목적은 아로니아 식초를 유효성분으로 포함하는 염증의 예방 및/또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing and / or improving inflammation containing aronia vinegar as an active ingredient.
하나의 양태로서, 본 발명은 아로니아 식초를 유효성분으로 포함하는 항염증용 조성물을 제공한다.As one aspect, the present invention provides an anti-inflammatory composition comprising aronia vinegar as an active ingredient.
본 발명에 있어서, 상기 아로니아 식초는 아로니아 열매 파쇄물의 주정 추출물과 배 농축액을 혼합하고 이를 알코올 발효 후 숙성한 다음 초산 발효하고 원심분리에 의한 상층액을 말한다.In the present invention, the aronia vinegar refers to the supernatant by mixing the alcohol extract and pear concentrate of the aronia fruit lysate, aging it after alcohol fermentation, fermenting it with acetic acid, and centrifuging.
구체적으로, 상기 아로니아 식초는 아로니아 파쇄물을 제조하는 단계; 상기 아로니아 파쇄물에 배 농축액을 첨가하는 단계; 상기 배 농축액이 첨가된 아로니아 파쇄물을 주정 추출하는 단계; 상기 아로니아 파쇄물의 주정 추출물을 알코올 발효하여 아로니아 와인을 제조하는 단계; 상기 아로니아 와인을 초산 발효하는 단계; 및 상기 초산 발효물을 원심분리하여 아로니아 식초인 상층액을 수득하는 단계;를 포함한다.Specifically, the aronia vinegar comprising the steps of preparing aronia lysate; Adding pear concentrate to the aronia lysate; Alcohol extraction of the aronia lysate to which the pear concentrate is added; Preparing Aronia wine by alcoholic fermentation of the alcohol extract of the Aaronia lysate; Acetic acid fermentation of the Aronia wine; And centrifuging the acetic acid fermentation product to obtain a supernatant of aronia vinegar; includes.
이하, 상기 아로니아 식초의 제조 방법을 구체적으로 설명한다.Hereinafter, the manufacturing method of the aronia vinegar will be described in detail.
먼저, 아로니아 파쇄물을 제조하는 단계이다.First, it is a step of preparing aronia lysate.
본 발명에 있어서, 상기 아로니아는 아로니아 열매를 말하며, 상기 아로니아 파쇄물은 믹서기, 분쇄기 등의 통상의 방법에 의하여 아로니아 열매를 분쇄한 것을 말한다.In the present invention, the aronia refers to aronia fruit, and the aronia lye refers to grinding the aronia fruit by a conventional method such as a mixer or grinder.
다음으로, 상기 아로니아 파쇄물에 배 농축액을 첨가하는 단계이다.Next, it is a step of adding pear concentrate to the aronia lysate.
상기 배 농축액은 배의 추출물을 농축한 것을 말하는데, 상기 배의 추출물은 물 또는 유기용매를 사용하여 추출할 수 있으나, 바람직하게는 배의 물 추출물, 보다 바람직하게는 배의 열수 추출물이다.The pear concentrate refers to a concentrated pear extract. The pear extract may be extracted using water or an organic solvent, but is preferably a water extract of the pear, more preferably a hot water extract of the pear.
상기 배 농축액은 상기 아로니아 파쇄물 100 중량%를 기준으로 1.5 내지 2.5 중량%, 바람직하게는 1.8 내지 2.2 중량%, 보다 바람직하게는 2중량%의 함량으로 첨가한다. 상기 배 농축액의 함량이 1.5 중량% 미만인 경우 이후 제조되는 아로니아 와인의 알코올 함량이 목적 수준(즉, 10% 이상)에 도달하지 못하며, 상기 배 농축액의 함량이 2.5 중량% 초과인 경우 그 함량에 비하여 이후 제조되는 아로니아 와인의 알코올 함량의 큰 증가를 기대할 수 없다.The pear concentrate is added in an amount of 1.5 to 2.5% by weight, preferably 1.8 to 2.2% by weight, more preferably 2% by weight based on 100% by weight of the aronia lysate. If the content of the pear concentrate is less than 1.5% by weight, the alcohol content of the aronia wine produced thereafter does not reach the target level (ie, 10% or more), and if the content of the pear concentrate exceeds 2.5% by weight, the content In comparison, a large increase in the alcohol content of Aronia wine produced later cannot be expected.
하나의 구체적 실시에서, 상기 배 농축액을 아로니아 파쇄물 100 중량%를 기준으로 1중량% 사용한 경우 2중량% 사용한 경우와 비교하여 제조된 아로니아 와인의 알코올 함량이 10% 미만이었으며, 효모 대사 산물 중의 하나인 베타글루칸의 함량도 현저히 감소한 것을 확인할 수 있었다.In one specific embodiment, when 1% by weight of the pear concentrate was used based on 100% by weight of aronia lysate, the alcohol content of the prepared aronia wine was less than 10% compared to when 2% by weight was used, and yeast metabolites It was confirmed that the content of one, beta-glucan, was also significantly reduced.
다음으로, 상기 배 농축액이 첨가된 아로니아 파쇄물을 주정 추출하는 단계이다.Next, it is a step of extracting alcohol from the aronia lysate to which the pear concentrate is added.
상기 주정 추출은 주정의 농도가 20 내지 80%, 바람직하게는 50 내지 80%, 보다 바람직하게는 60 내지 80%, 가장 바람직하게는 70%인 주정으로 추출한 것을 말한다.The alcohol extraction refers to extraction with alcohol having an alcohol concentration of 20 to 80%, preferably 50 to 80%, more preferably 60 to 80%, and most preferably 70%.
하나의 구체적 실시에서, 주정의 농도를 달리하여 배 농축액이 첨가된 아로니아 파쇄물을 주정 추출하였을 때 주정의 농도가 20% 이상인 경우 발효에 사용되는 당인 환원당이 20% 이상이었다. 효모 발효에 의한 알코올 함량은 환원당의 1/2 수준에 해당한다는 종래의 연구결과에 비추어 볼 때 주정 추출물의 환원당 함량이 20% 이상이어야만 이후 제조되는 아로니아 와인의 알코올 함량이 목적 수준(즉, 10% 이상)에 도달할 수 있으므로, 주정의 농도가 최소 18% 이상, 바람직하게는 20% 이상인 것이 바람직하다. 다만, 주정의 농도가 70%인 경우 다른 주정의 농도에 비하여 추출물 내 안토시아닌 함량이 가장 우수하므로 가장 바람직하게는 주정70%를 사용한다.In one specific implementation, when alcohol was extracted from aronia lysate to which pear concentrate was added at different concentrations of alcohol, reducing sugar, a sugar used in fermentation, was 20% or more when the concentration of alcohol was 20% or more. In view of the previous research results that the alcohol content by yeast fermentation corresponds to 1/2 of the reducing sugar level, the reducing sugar content of the alcohol extract must be 20% or more so that the alcohol content of the aronia wine produced thereafter reaches the target level (i.e., 10%). % or more), it is preferable that the concentration of alcohol is at least 18% or more, preferably 20% or more. However, when the alcohol concentration is 70%, the anthocyanin content in the extract is the highest compared to other alcohol concentrations, so 70% alcohol is most preferably used.
상기 주정 추출은 80 내지 100℃, 바람직하게는 90 내지 100℃에서 2 내지 4시간, 바람직하게 2.5 내지 3.5시간, 가장 바람직하게 3시간 동안 수행될 수 있다.The alcohol extraction may be performed at 80 to 100°C, preferably 90 to 100°C for 2 to 4 hours, preferably 2.5 to 3.5 hours, and most preferably 3 hours.
본 명세서에서는 상기 배 농축액이 첨가된 아로니아 파쇄물을 주정 추출하여 제조된 추출물을 편의상 아로니아 파쇄물의 주정 추출물이나 아로니아 주정 추출물로 사용할 수 있다.In the present specification, an extract prepared by extracting alcohol from the aronia lysate to which the pear concentrate is added may be used as an alcohol extract of the aronia lysate or an aronia lysate extract for convenience.
다음으로, 상기 아로니아 파쇄물의 주정 추출물을 알코올 발효하여 아로니아 와인을 제조하는 단계이다.Next, it is a step of producing Aronia wine by alcoholic fermentation of the alcohol extract of the aronia lysate.
상기 알코올 발효는 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 및 사카로마이세스 불라디이(Saccharomyces boulardii)으로 이루어진 군으로부터 선택된 1종 이상의 균주, 바람직하게는 사카로마이세스 세레비지애 및 카로마이세스 불라다이 혼합 균주, 보다 바람직하게는 사카로마이세스 세레비지애를 상기 아로니아 파쇄물의 주정 추출물에 접종하고 진탕 배양한 것을 말한다. 상기 사카로마이세스 세레비지애 균주로 알코올 발효할 경우 알코올 함량이 높은 아로니아 와인을 제조할 수 있으며, 상기 카로마이세스 불라다이 균주로 알코올 발효할 경우 베타글루칸 함량이 높은 아로니아 와인을 제조할 수 있다. 특히, 상기 카로마이세스 불라다이 균주는 본 출원인이 새로이 발견한 균주로서 한국생명공학연구원에 2019년 11월 18일자로 KCTC 14036BP로 기탁한 신규 균주이다.The alcoholic fermentation is carried out using one or more strains selected from the group consisting of Saccharomyces cerevisiae and Saccharomyces boulardii, preferably Saccharomyces cerevisiae and Caromyces It refers to a mixture of Buladai strains, more preferably Saccharomyces cerevisiae, inoculated into the alcohol extract of the aronia lysate and cultured with shaking. Aronia wine with high alcohol content can be produced when alcoholic fermentation is performed with the Saccharomyces cerevisiae strain, and Aronia wine with high beta-glucan content can be produced when alcoholic fermentation is performed with the Karomyces bulla strain. can In particular, the Karomyces Bulladi strain is a new strain deposited as KCTC 14036BP on November 18, 2019 with the Korea Research Institute of Bioscience and Biotechnology as a newly discovered strain by the present applicant.
상기 진탕 배양은 100 내지 130rpm으로 상온에서 70 내지 74시간 동안 이루어진다.The shaking culture is performed for 70 to 74 hours at room temperature at 100 to 130 rpm.
하나의 구체적 실시에서, 상기 알코올 발효이 70 내지 74시간, 바람직하게는 72시간 동안 수행된 경우 그 이하의 시간에 비하여 목적 수준의 알코올 함량을 가진 아로니아 와인을 제조할 수 있었다.In one specific implementation, when the alcoholic fermentation was performed for 70 to 74 hours, preferably 72 hours, it was possible to produce Aronia wine with a target level of alcohol content compared to less time.
상기 알코올 발효시 발효 균주의 접종은 상기 아로니아 파쇄물의 주정 추출물의 총 부피%를 기준으로 0.08 내지 0.12 부피%, 바람직하게는 0.09 내지 0.11 부피%, 가장 바람직하게는 0.1 부피%의 함량으로 이루어진다.During the alcohol fermentation, the inoculation of the fermentation strain is 0.08 to 0.12% by volume, preferably 0.09 to 0.11% by volume, and most preferably 0.1% by volume based on the total volume% of the alcohol extract of the aronia lysate.
본 명세서는 상기 아로니아 파쇄물의 주정 추출물의 알코올 발효에 의한 발효물을 편의상 아로니아 와인으로 통칭할 수 있다.In the present specification, the fermented product by alcoholic fermentation of the alcohol extract of the aronia lysate may be collectively referred to as aronia wine for convenience.
한편, 상기 제조된 아로니아 와인은 이후의 초산 발효 전에 여과할 수 있다. 하나의 구체적 예로서, 상기 여과는 1차 부직포 필터, 2차 페이퍼 필터 순으로 이루어질 수 있다. 이러한 여과에 의하여 이후 초산 발효가 원활히 이루어질 수 있다.On the other hand, the prepared aronia wine may be filtered before subsequent acetic acid fermentation. As one specific example, the filtration may be performed in the order of a primary non-woven fabric filter and a secondary paper filter. After this filtration, acetic acid fermentation can be performed smoothly.
또한, 상기 제조된 아로니아 와인은 이후의 초산 발효 전에 오크통에서 1 내지 3개월, 바람직하게는 2개월 동안 숙성할 수 있다. 상기 숙성은 상기 여과 전 또는 후에 이루어질 수 있으며, 바람직하게는 여과 후에 이루어질 수 있다. 이러한 숙성에 의하여 아로니아 와인의 pH, 산도, 당도 등은 거의 변함이 없으나, 아로니아 와인의 맛과 향이 기호에 적합한 효과가 있다.In addition, the prepared aronia wine may be aged for 1 to 3 months, preferably 2 months, in oak barrels before subsequent acetic acid fermentation. The aging may be performed before or after the filtration, preferably after filtration. By this aging, the pH, acidity, sugar content, etc. of Aronia wine are almost unchanged, but the taste and aroma of Aronia wine have an effect suitable for the taste.
다음으로, 상기 아로니아 와인에 초산 발효하는 단계이다.Next, it is a step of acetic acid fermentation in the aronia wine.
상기 초산 발효는 초산균을 접종하고 상온에서 160 내지 170시간, 바람직하게는 165 내지 170 시간, 보다 바람직하게는 166 내지 170 시간, 가장 바람직하게는 168 시간 동안 상온에서 발효하는 것을 말한다.The acetic acid fermentation refers to inoculation of acetic acid bacteria and fermentation at room temperature for 160 to 170 hours, preferably 165 to 170 hours, more preferably 166 to 170 hours, and most preferably 168 hours at room temperature.
또한 상기 초산 발효는 발효 과정 중에 1일당 1시간씩 공기 주입을 하는 것이 바람직하다. 이러한 공기 주입에 의하여 초산 발효가 효과적으로 진행되어 목적 수준의 pH, 산도, 당도 등을 가지는 초산 발효물을 제조할 수 있다.In the acetic acid fermentation, it is preferable to inject air for 1 hour per day during the fermentation process. Acetic acid fermentation is effectively progressed by such air injection, and a fermented acetic acid product having a desired level of pH, acidity, sugar content, etc. can be produced.
상기 초산균은 아세토박터 속 균주, 바람직하게는 아세토박터 아세티(Acetobacter aceti)이며, 아로니아 와인의 총 부피%를 기준으로 0.8 내지 1.2 부피%, 바람직하게는 0.9 내지 1.1 부피%, 가장 바람직하게는 1 부피%의 함량으로 접종한다.The acetobacter is a strain of the genus Acetobacter, preferably Acetobacter aceti, and is 0.8 to 1.2% by volume, preferably 0.9 to 1.1% by volume, most preferably 0.9 to 1.1% by volume, based on the total volume% of Aronia wine. It is inoculated with an amount of 1% by volume.
상술한 조건에서 초산 발효를 한 경우 발효물의 pH 및 산도, 알코올 함량 등이 아로니아 식초 음료의 맛과 향에 적합할 정도로 함유되어 있다.In the case of acetic acid fermentation under the above-mentioned conditions, the pH, acidity, and alcohol content of the fermented product are contained enough to suit the taste and aroma of the aronia vinegar beverage.
다음으로, 상기 초산 발효물을 원심분리하여 아로니아 식초인 상층액을 수득하는 단계이다.Next, it is a step of centrifuging the acetic acid fermentation product to obtain a supernatant of aronia vinegar.
상기 원심분리에 의한 상층액은 아로니아 식초이지만, 원심분리에 의한 침전물은 아로니아 식초 부산물로서 열풍건조 등의 방법으로 건조하여 분말화하고 식품 등의 소재로 사용할 수 있다.The supernatant by centrifugation is aronia vinegar, but the precipitate by centrifugation is a by-product of aronia vinegar and can be dried and powdered by a method such as hot air drying and used as a material such as food.
본 명세서에서 상기 초산 발효물의 원심분리에 의한 상층액을 아로니아 식초라 하며, 초산 발효물의 원심분리에 의한 침전물을 아로니아 식초 부산물 또는 아로니아 발효 부산물이라 한다.In this specification, the supernatant obtained by centrifugation of the acetic acid fermentation is referred to as aronia vinegar, and the precipitate obtained by centrifugation of the acetic acid fermentation is referred to as aronia vinegar by-product or aronia fermentation by-product.
상기한 방법에 의하여 제조된 아로니아 식초는 아로니아 식초 부산물과 대비하여 NO 억제 활성이 우수하고 싸이토카인 중 IL-6의 생성을 억제하였다. 따라서, 상기 아로니아 식초는 항염증 용도로서 유용하다.Aronia vinegar prepared by the above method had excellent NO inhibitory activity and inhibited the production of IL-6 among cytokines compared to aronia vinegar by-products. Thus, the aronia vinegar is useful as an anti-inflammatory application.
본 발명의 상기 항염증용 조성물은 염증의 예방 및/또는 치료용 약학 조성물, 및 염증의 예방 및/또는 개선용 식품 조성물로서 사용될 수 있다.The anti-inflammatory composition of the present invention can be used as a pharmaceutical composition for preventing and/or treating inflammation, and a food composition for preventing and/or improving inflammation.
하나의 구체적 양태로서, 본 발명은 아로니아 식초를 포함하는 염증의 예방 및/또는 치료용 약학 조성물을 제공한다.As one specific aspect, the present invention provides a pharmaceutical composition for preventing and / or treating inflammation containing aronia vinegar.
본 발명의 약학 조성물에 함유되는 아로니아 식초는 상술한 바와 같다.Aronia vinegar contained in the pharmaceutical composition of the present invention is as described above.
본 발명의 약학 조성물은 유효성분으로 아로니아 식초 이외에 항염증 효과가 공지된 다른 물질, 특히 천연 소재 유래 물질을 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may further include other substances known to have anti-inflammatory effects, in particular substances derived from natural materials, in addition to aronia vinegar as an active ingredient.
상기 본 발명의 약학 조성물은 약학적으로 허용가능한 담체를 추가로 포함할 수 있다. 본 발명의 용어 "약학적으로 허용가능한"이란 상기 조성물에 노출되는 세포나 인간에게 독성이 없는 특성을 나타내는 것을 의미한다. 상기 담체는 완충제, 보존제, 무통화제, 가용화제, 등장제, 안정화제, 기제, 부형제, 윤활제 등 당업계에 공지된 것이라면 제한없이 사용할 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" of the present invention means exhibiting characteristics that are not toxic to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art such as a buffer, a preservative, a pain reliever, a solubilizer, an isotonic agent, a stabilizer, a base, an excipient, a lubricant, and the like.
또한, 본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 나아가, 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태의 피부 외용제의 형태로 사용될 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In addition, the pharmaceutical composition of the present invention is formulated according to conventional methods into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions. can Furthermore, it may be used in the form of ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or skin external preparations in the form of gels. Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 아로니아 식초에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the aronia vinegar, for example, starch, calcium carbonate, sucrose It is prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, and lyophilized formulations. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
한편, 본 발명의 약학 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명의 용어 "투여"란, 적절한 방법으로 개체에게 소정의 물질을 도입하는 것을 의미하며 상기 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 국소 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있으나, 이에 제한되지는 않는다.Meanwhile, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administration" of the present invention means introducing a predetermined substance into a subject by an appropriate method, and the administration route of the composition may be administered through any general route as long as it can reach the target tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration, but not limited thereto.
상기 용어 "개체"란 는 인간을 포함한 쥐, 생쥐, 가축 등의 모든 동물을 의미한다. 바람직하게는, 인간을 포함한 포유동물일 수 있다.The term "individual" refers to all animals such as rats, mice, and livestock, including humans. Preferably, it may be a mammal including a human.
상기 용어 "약학적으로 유효한 양"이란 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효 용량 수준은 환자의 성별, 연령, 체중, 건강상태, 질병의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로, 및 배출 비율, 치료 기간, 배합 또는 동시에 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 당업자에 의해 용이하게 결정될 수 있다. 투여는 상기 권장 투여량을 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다.The term "pharmaceutically effective amount" means an amount that is sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level is determined by the patient's sex, age, and weight , health condition, type of disease, severity, activity of drug, sensitivity to drug, method of administration, time of administration, route of administration, and excretion rate, duration of treatment, factors including drugs used in combination or concomitantly, and other medical fields well known. It can be easily determined by a person skilled in the art according to known factors. Administration may be administered once a day at the recommended dose, or may be administered in several divided doses.
다른 하나의 구체적 양태로서, 본 발명은 아로니아 식초를 포함하는 염증의 예방 및/또는 개선용 식품 조성물을 제공한다.As another specific aspect, the present invention provides a food composition for preventing and / or improving inflammation containing aronia vinegar.
본 발명의 조성물을 식품 첨가물로 사용할 경우, 상기 아로니아 식초를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상의 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있으며, 식품학적으로 허용가능한 식품 보조 첨가제를 추가로 포함할 수 있다. 본 발명의 조성물은 천연물 추출물의 분획물 유래 화합물을 유효성분으로 하므로 안정성 면에서 문제가 없기 때문에 혼합량에 큰 제한은 없다.When the composition of the present invention is used as a food additive, the aronia vinegar may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment), and may further include food additives acceptable in food science. Since the composition of the present invention uses a compound derived from a fraction of a natural extract as an active ingredient, there is no problem in terms of stability, so there is no great limitation on the mixing amount.
본 발명의 식품 조성물은 통상적인 의미의 식품을 모두 포함할 수 있으며, 기능성 식품, 건강기능식품 등 당업계에 알려진 용어와 혼용 가능하다.The food composition of the present invention may include all food in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food and health functional food.
본 발명의 용어 "기능성 식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The term "functional food" of the present invention refers to food manufactured and processed using raw materials or ingredients having useful functionality for the human body in accordance with the Act on Health Functional Foods No. 6727, and "functional" refers to the structure of the human body. And it refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients for functions or physiological functions.
또한, 본 발명의 용어 "건강기능식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품 원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 상기 건강식품용 조성물은 질병의 예방 및 질병의 회복 등과 관련된 기능을 수행할 수 있다.In addition, the term "health functional food" of the present invention refers to food manufactured and processed by using specific ingredients as raw materials or by extracting, concentrating, refining, mixing, etc. specific ingredients contained in food ingredients for the purpose of health supplementation. It refers to food designed and processed by the above ingredients to sufficiently exert bioregulatory functions such as biodefense, regulation of biorhythm, prevention and recovery of disease, etc. It can perform functions related to recovery, etc.
본 발명의 조성물이 사용될 수 있는 식품의 종류에는 제한이 없다. 아울러 본 발명의 아로니아 식초를 활성성분으로 포함하는 조성물은 당업자의 선택에 따라 식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 아로니아 식초를 주성분으로 하여 제조한 젤리 및 주스 등에 첨가하여 제조할 수 있다.There are no restrictions on the types of foods in which the composition of the present invention can be used. In addition, the composition containing the aronia vinegar of the present invention as an active ingredient can be prepared by mixing suitable other auxiliary ingredients that may be contained in food and known additives according to the selection of those skilled in the art. Examples of food that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and it can be prepared by adding aronia vinegar according to the present invention to jellies and juices prepared as a main component.
또한, 본 발명에 적용될 수 있는 식품에는 예컨대, 특수영양식품(예: 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예: 라면류, 국수류 등), 건강보조식품, 조미식품(예: 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예:스낵류), 유가공품(예: 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예: 과실, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등) 등 모든 식품을 포함할 수 있다.In addition, foods that can be applied to the present invention include, for example, special nutritional foods (e.g., formula milk, infant, baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), health supplement food , seasonings (eg soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.) ), beverages (eg fruit, vegetable drinks, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.).
본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavoring agents, or natural carbohydrates as additional components, like conventional beverages. In addition to the above, the health functional food composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, and glycerin. , alcohol, a carbonating agent used in carbonated beverages, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages.
본 발명에 따른 아로니아 식초는 대식세포에서 NO 활성을 억제하고 IL-6의 생성을 억제하므로 염증의 예방, 개선, 및 치료를 위한 약학 및 식품 조성물로서 유용하다. 더욱이 본 발명에 따른 아로니아 식초는 세포독성이 없고 천연 아로니아로부터 유래한 물질이므로 인간을 포함한 동물에 안전하게 사용 가능하다.Aronia vinegar according to the present invention inhibits NO activity in macrophages and inhibits the production of IL-6, so it is useful as a pharmaceutical and food composition for preventing, improving, and treating inflammation. Moreover, since the aronia vinegar according to the present invention is non-cytotoxic and is a material derived from natural aronia, it can be safely used in animals including humans.
도 1은 본 발명의 일 실시예에 따른 아로니아 식초의 대량 생산을 위한 최적 공정 순서도이다.
도 2는 본 발명의 일 실시예에 따른 아로니아 식초 및 아로니아 식초 부산물의 세포독성을 확인한 그림이다.
도 3은 본 발명의 일 실시예에 따른 아로니아 식초 및 아로니아 식초 부산물의 NO 억제 활성을 확인한 그림이다.
도 4는 본 발명의 일 실시예에 따른 아로니아 식초 및 아로니아 식초 부산물의 싸이토카인의 생성량을 확인한 그림이다.1 is an optimal process flow chart for mass production of aronia vinegar according to an embodiment of the present invention.
Figure 2 is a picture confirming the cytotoxicity of aronia vinegar and aronia vinegar by-products according to an embodiment of the present invention.
Figure 3 is a picture confirming the NO inhibitory activity of aronia vinegar and aronia vinegar by-products according to an embodiment of the present invention.
Figure 4 is a picture confirming the production of cytokines of aronia vinegar and aronia vinegar by-products according to an embodiment of the present invention.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples and the like will be described in detail to aid understanding of the present invention. However, the embodiments according to the present invention can be modified in many different forms, and the scope of the present invention should not be construed as being limited to the following examples. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
실시예 1: 아로니아 발효물 생산을 위한 최적의 효모 균주 실험Example 1: Optimal yeast strain experiment for producing fermented aronia
아로니아 재배 농가에서 직접 구매한 아로니아 열매를 세척하고 블렌더(Mufti Quick 7-MQ736, ㈜ BRAUN, Germany)로 파쇄하였다. 그 아로니아 파쇄물 1L를 본 실험의 배지로 사용하였으며, 배지를 121℃에서 15분간 살균 후 2시간 방냉 하였다. 이후 일반 맥주나 빵 발효 시 사용하는 효모로 알려진 사카로마이세스 세레비지애(Saccharomyces cerevisiae (KCTC NO. 27756)), 본 출원인이 발견한 신규 균주인 사카로마이세스 불라디이(Saccharomyces boulardii srcnm 001), 콤부차 찻잎에서 발견되어 내산성 효모로 알려진 카카크스트니아 세르바지이(Kazachstnia servazzii), 균의 대사산물이 화장품으로 사용되는 갈락토마이세스 게오트리쿰(Galactomyces geotrichum) 4종을 배지 부피의 0.1% 접종하여 120rpm에서 27℃에서 44~46시간 동안 배양하였다. 배양 후 4종의 효모 발효에 의한 아로니아 파쇄물의 발효 특성을 하기와 같이 분석하였다.Aronia fruits purchased directly from aronia cultivating farms were washed and crushed with a blender (Mufti Quick 7-MQ736, BRAUN, Germany). 1 L of the aronia lysate was used as a medium for this experiment, and the medium was sterilized at 121 ° C for 15 minutes and then allowed to cool for 2 hours. Since then, Saccharomyces cerevisiae (KCTC NO. 27756), known as yeast used for fermentation of beer or bread, and Saccharomyces boulardii srcnm 001, a new strain discovered by the present applicant , Kazachstnia servazzii, known as an acid-resistant yeast found in kombucha tea leaves, and 4 species of Galactomyces geotrichum, whose metabolites are used as cosmetics, were added at 0.1% of the volume of the medium. Inoculated and incubated at 120 rpm at 27 ° C for 44 to 46 hours. After cultivation, the fermentation characteristics of the aronia lysate by four types of yeast fermentation were analyzed as follows.
실험 방법Experiment method
1) pH, 적정 산도 및 아미노산도 측정 1) Measurement of pH, titratable acidity and amino acid degree
발효물의 pH는 시료 1 mL에 증류수 9 mL을 가하여 희석한 후 pH meter (pH-meter P-71, HORIBA, Kyoto, Japan)를 이용하여 측정하였다. 적정 산도는 시료 1 mL과 NaOH 1mL를 혼합 후 1% Phenolphthalein solution 시약을 떨어뜨려 색이 변하는 구간을 확인 후 적정하여 값을 구하였다. 아미노산도는 시료 1mL에 증류수 9 mL을 가한 다음 pH 8.3에 도달 시까지 0.1 N NaOH로 적정하여 사용된 소비량을 tartaric acid 함량(%, v/v)으로 환산하여 실험하였다.The pH of the fermentation product was diluted by adding 9 mL of distilled water to 1 mL of the sample, and then measured using a pH meter (pH-meter P-71, HORIBA, Kyoto, Japan). The titratable acidity was obtained by titrating after mixing 1 mL of sample and 1 mL of NaOH, dropping a 1% Phenolphthalein solution reagent, and checking the color change section. The amino acid level was tested by adding 9 mL of distilled water to 1 mL of sample, titrating with 0.1 N NaOH until reaching pH 8.3, and converting the amount used into tartaric acid content (%, v/v).
2) 환원당 함량 측정 2) Measurement of reducing sugar content
발효물의 환원당 함량은 dinitro salicylic acid (DNS) 법에 따라 측정하였다. 발효물을 원심분리(1,500 xg, 20 min)하여 얻은 상등액을 희석한 시료액 1mL에 DNS 시약 3 mL을 첨가하고, 5분간 100℃에서 발색시켰다. 50분간 암소에서 실온으로 냉각한 후 550nm에서 흡광도를 측정하였다. 환원당 함량은 표준물질을 glucose로 하여 표준 곡선을 작성한 후 산출하였다.The reducing sugar content of the fermentation product was measured according to the dinitro salicylic acid (DNS) method. 3 mL of DNS reagent was added to 1 mL of a diluted sample solution of the supernatant obtained by centrifugation of the fermented product (1,500 xg, 20 min), and the color was developed at 100 ° C. for 5 minutes. After cooling to room temperature in the dark for 50 minutes, absorbance was measured at 550 nm. The reducing sugar content was calculated after preparing a standard curve using glucose as the standard material.
3) 총당 함량 측정3) Measurement of total sugar content
발효물의 총당 함량 측정은 페놀-황산법을 이용하여 측정하였다. 발효물을 2배 희석한 후 1 mL을 정량한 후 페놀 용액 1 mL을 가하여 잘 혼합하였다. 이후 진한 황산 5 mL을 첨가하여 가능한 한 강하게 발열시켜 반응시켰다. 황산을 가한 후 실온에서 40분간 방치 후 470nm에서 흡광도를 측정하였다. 총당 함량은 표준물질을 glucose로 하여 표준 곡선을 작성한 후 산출하였다.The total sugar content of the fermented product was measured using the phenol-sulfuric acid method. After 2-fold dilution of the fermented product, 1 mL of the mixture was weighed, and then 1 mL of phenol solution was added and mixed well. Thereafter, 5 mL of concentrated sulfuric acid was added and reacted by exotherm as strongly as possible. After adding sulfuric acid, the mixture was allowed to stand at room temperature for 40 minutes, and absorbance was measured at 470 nm. The total sugar content was calculated after preparing a standard curve using glucose as the standard material.
4) °Brix (Soluble sugar content ) 함량 측정4) Measurement of °Brix (Soluble sugar content) content
발효물의 Brix 함량 측정은 당도계인 (Pocket refractometer PAL-2, ㈜ATAGO, Kyoto, Japan)를 이용하여 측정하였다. 발효물 500 ul를 정량 후 3회 반복 측정하여 평균값을 산출하였다. 측정 시 증류수를 이용하여 영점을 맞춘 후 실험을 진행하였다.The Brix content of the fermented product was measured using a sugar meter (Pocket refractometer PAL-2, ATAGO, Kyoto, Japan). After quantifying 500 ul of the fermented product, the average value was calculated by repeating the measurement three times. When measuring, the experiment was conducted after adjusting the zero point using distilled water.
5) 생균 수 (viable cell count) 측정5) Measurement of viable cell count
발효물의 생균 수는 발효물 1 mL을 취하여 멸균 생리식염수로 10배 희석법으로 104, 105, 106 배로 단계별 희석하여 배지에 20μL 도말한 후, 30℃ 항온배양기(Shaking incubator, ㈜ 대원 과학, Jaecheon, Korea)에서 24시간 동안 배양하여 형성된 colony 집락을 계수하여 colony forming unit (CFU/mL)로 나타내었다.The number of viable cells in the fermented product was taken by taking 1 mL of the fermented product, diluted 10 4 , 10 5 , and 10 6 stepwise with sterile physiological saline by a 10-fold dilution method, smeared 20 μL on the medium, and then placed in a 30 ° C incubator (Shaking incubator, Daewon Science, Co., Ltd.). Jaecheon, Korea), colony colonies formed by culturing for 24 hours were counted and expressed as colony forming unit (CFU/mL).
6) 베타글루칸 함량 측정6) Measurement of beta glucan content
베타글루칸 함량은 Megazyme Kit (Mushroom and Yeast β-glucan Assay Procedure K-YBGL)을 이용하여 분석하였다. 흡광도 510nm에서 측정된 총 글루칸(total glucan)과 알파 글루칸(α-glucan) 측정값은 glucose 용액 (1mg/mL)을 GOPOD 시약과 반응시킨 반응액의 흡광도 값과 함께 www.megazyme.com 홈페이지의 Mega-Calc 함량 계산식을 참고하여 함량(%, w/w) 값으로 계산하였다. 최종적으로 베타글루칸은 전부 글루칸 함량에서 알파 글루칸 함량을 빼 준 값으로 계산하였다. 하기 수학식 1은 식약처 건강기능 식품 공전에 맞춰 실험을 진행하였다.Beta-glucan content was analyzed using Megazyme Kit (Mushroom and Yeast β-glucan Assay Procedure K-YBGL). The measured values of total glucan and α-glucan measured at absorbance 510nm are available on the website of www.megazyme.com along with the absorbance value of the reaction solution obtained by reacting glucose solution (1mg/mL) with the GOPOD reagent. Calculated by referring to the calculation formula for the content of Calc content (%, w / w). Finally, beta-glucan was calculated by subtracting the alpha-glucan content from the total glucan content. In Equation 1 below, the experiment was conducted in accordance with the Ministry of Food and Drug Safety health functional food regulations.
[수학식 1][Equation 1]
총 글루칸 함량 (mg/g)= C X (a X b )/S X 0.9 Total glucan content (mg/g) = C X (a X b )/S X 0.9
알파 글루칸 함량 (mg/g) = C X (a X b )/S X 0.9 Alpha glucan content (mg/g) = C X (a X b )/S X 0.9
베타글루칸 함량 (mg/g) = 총 글루칸 함량- 알파 글루칸Beta glucan content (mg/g) = total glucan content - alpha glucan
C: 시험용액의 농도 (ug/mL)C: Concentration of test solution (ug/mL)
a: 시험용액의 전량 (mL) a: Total amount of test solution (mL)
b: 희석 배수 b: dilution factor
S: 시료 중량 (mg)S: sample weight (mg)
0.9: 베타글루칸 전환계수 (160/180)0.9: beta glucan conversion factor (160/180)
7) DO, BOD 측정7) DO, BOD measurement
발효물의 용존산소량 및 생물화학적 산소요구량 측정은 (DO-31P, ㈜ TOADKK, Tokyo, Japan)를 이용하여 측정하였다. 발효물을 15mL 정량하여 3회 반복하여 평균값을 산출하였다. 단, 발효 0일 차의 용존산소량은 100%, 생물학적 산소요구량은 0%로 환산하여 실험을 진행하였다.The amount of dissolved oxygen and biochemical oxygen demand of the fermentation product were measured using (DO-31P, TOADKK Co., Ltd., Tokyo, Japan). 15 mL of the fermented product was quantified and repeated three times to calculate the average value. However, the amount of dissolved oxygen on the 0th day of fermentation was converted to 100% and the biological oxygen demand was converted to 0%, and the experiment was conducted.
8) 알코올 함량 측정8) Alcohol content measurement
발효물의 알코올 함량은 국세청 주류분석규정에 따라 측정하였다. 메스실린더에 시료 100mL를 취한 후 500mL 삼각 플라스크에 옮겼다. 시료가 넣어져 있던 메스실린더를 증류수 10mL로 3회 씻은 후 그 액을 삼각 플라스크에 합쳤다. 냉각기 한쪽에 삼각 플라스크를 연결하여 다른 한쪽에는 수기로 100mL 메스실린더를 연결하였다. Soxhlet heater를 이용하여 시료에 열을 가하였다. 증류액이 70mL가 되면 증류를 정지하고 증류수를 보충하여 메스실린더의 100mL 눈금까지 정용하였다. 잘 흔들어 주정계로 측정한 후 주정 도수 환산표에 의해 온도 보정을 시행하였다.The alcohol content of the fermented product was measured according to the liquor analysis regulations of the National Tax Service. After taking 100mL of the sample in a measuring cylinder, it was transferred to a 500mL Erlenmeyer flask. The measuring cylinder into which the sample was placed was washed three times with 10 mL of distilled water, and the solution was combined with an Erlenmeyer flask. An Erlenmeyer flask was connected to one side of the cooler, and a 100mL measuring cylinder was connected to the other side with a water pipe. Heat was applied to the sample using a Soxhlet heater. When the distillate reached 70mL, distillation was stopped, and distilled water was replenished, and the measuring cylinder was used up to the 100mL mark. After shaking well and measuring with a spirit meter, temperature correction was performed by the alcohol frequency conversion table.
9) 통계처리 9) Statistical processing
실험 결과는 평균값과 표준편차 (mean±SD)로 나타내었으며, 통계처리는 SPSS (statist ictal package for social science, 24, SPSS Inc. Chicago, IL, USA)를 이용하여 one-way ANOVA 분석한 후 Duncan’s multiple range test로 유의성을 P<0.05 수준에서 검증하였다.The experimental results were expressed as mean values and standard deviations (mean±SD), and statistical processing was performed by one-way ANOVA using SPSS (statist ictal package for social science, 24, SPSS Inc. Chicago, IL, USA), followed by Duncan's Significance was verified at the P<0.05 level by a multiple range test.
실험 결과Experiment result
아로니아 효모 4종 균주에 대한 알코올 발효의 pH 변화는 표 1과 같다. pH는 효모 발효 시간에 따라 소폭 감소하는 경향을 보였으나 이는 효모 발효 시간에 따른 이상 발효를 하지 않고 정상적으로 발효가 진행되었음을 알 수 있었다. S. cerevisiae 균주는 발효 시작 4.24±0.01에서 발효 46시간 3.64±0.02로 소폭 감소하는 경향을 보였다.Table 1 shows the pH change of alcohol fermentation for four strains of Aronia yeast. pH showed a tendency to decrease slightly with yeast fermentation time, but it was found that fermentation proceeded normally without abnormal fermentation according to yeast fermentation time. S. cerevisiae showed a slight decrease from 4.24±0.01 at the beginning of fermentation to 3.64±0.02 at 46 hours of fermentation.
아로니아 효모 4종 균주에 대한 알코올 발효의 산도 변화는 표 2와 같다. 산도의 경우 효모 발효 시간에 따른 소폭 증가하는 경향을 보였으나 이는 효모 발효에 영향을 미치지 않는 것으로 나타났다. S. cerevisiae 균주는 발효 시작 0.65±0.02에서 발효 46시간 0.77±0.01로 소폭 증가하는 경향을 보였다.Table 2 shows the acidity change of alcoholic fermentation for four strains of Aronia yeast. In the case of acidity, there was a tendency to increase slightly with yeast fermentation time, but it was found that it did not affect yeast fermentation. The S. cerevisiae strain showed a slight increase from 0.65±0.02 at the beginning of fermentation to 0.77±0.01 at 46 hours of fermentation.
아로니아 효모 4종 균주에 대한 알코올 발효의 아미노산도 변화는 표 3과 같다. 아미노산의 경우 효모 발효 시간에 따른 소폭 증가하는 경향을 보였으나 이는 효모 발효에 영향을 미치지 않는 것으로 나타났다. S. cerevisiae 균주는 발효 시작 0.68±0.02에서 발효 46시간 0.86±0.01로 소폭 증가하는 경향을 보였다.Changes in the amino acid degree of alcohol fermentation for four strains of Aronia yeast are shown in Table 3. In the case of amino acids, there was a tendency to increase slightly with yeast fermentation time, but this did not appear to affect yeast fermentation. The S. cerevisiae strain showed a slight increase from 0.68±0.02 at the beginning of fermentation to 0.86±0.01 at 46 hours of fermentation.
아로니아 효모 4종 균주에 대한 알코올 발효의 총당 변화는 표 4와 같다. 총당의 경우 효모 발효 시간에 따른 감소하였으며 이는 효모 발효 균주의 당대사과정에 따른 감소 추세로 나타났다. S. cerevisiae 균주는 발효 시작 8.52±1.42에서 발효 46시간 0.98±0.32로 S. boulardii 균주 다음으로 당대사과정에 의한 높게 감소하는 경향을 보였다.Table 4 shows the total sugar changes in alcohol fermentation for four strains of Aronia yeast. In the case of total sugar, it decreased according to the yeast fermentation time, which was shown to decrease according to the sugar metabolism process of the yeast fermentation strain. The S. cerevisiae strain showed a tendency to decrease from 8.52±1.42 at the start of fermentation to 0.98±0.32 after 46 hours of fermentation, following S. boulardii strain, by sugar metabolism.
아로니아 효모 4종 균주에 대한 알코올 발효의 환원당 변화는 표 5와 같다. 환원당의 경우 효모 발효 시간에 따른 감소하였으며 이는 효모 발효 균주의 당대사과정에 따른 총당과 동일한 감소 추세로 나타났다. S. cerevisiae 균주는 발효 시작 5.52±0.66에서 발효 46시간 0.55±0.23로 S. boulardii 균주 다음으로 당대사과정에 의한 총당과 동일하게 높게 감소하는 경향을 보였다.Table 5 shows the changes in reducing sugars in alcohol fermentation for four strains of Aronia yeast. In the case of reducing sugar, it decreased according to yeast fermentation time, which showed the same decreasing trend as total sugar according to the sugar metabolism process of yeast fermentation strain. The S. cerevisiae strain showed a tendency to decrease from 5.52±0.66 at the beginning of fermentation to 0.55±0.23 after 46 hours of fermentation, the same as the total sugar by the sugar metabolism process next to the S. boulardii strain.
아로니아 효모 4종 균주에 대한 알코올 발효의 생균수 변화는 표 6과 같다. 생균수의 경우 효모 발효 0시간을 0으로 기준으로 했을 경우 S. cerevisiae 균주는 발효 시작 5.52±0.66에서 발효 46시간 0.55±0.23로 S. boulardii 균주 다음으로 당대사과정에 의한 총당과 동일하게 높게 감소하는 경향을 보였다.Table 6 shows the changes in the number of viable cells in alcohol fermentation for four strains of Aronia yeast. In the case of the viable cell count, when 0 hour of yeast fermentation was set as 0, the S. cerevisiae strain decreased from 5.52±0.66 at the beginning of fermentation to 0.55±0.23 at 46 hours of fermentation, following S. boulardii strain, as high as total sugar by glycolysis. showed a tendency to
아로니아 효모 4종 균주에 대한 알코올 발효의 알코올 함량 변화는 표 7과 같다. 알코올 함량의 경우 효모 발효 0시간을 0으로 기준으로 했을 경우 S. cerevisiae 균주는 발효 시작 0에서 발효 46시간 3.10±0.10로 당대사로 알코올 함량이 가장 높게 만드는 것을 확인하였다.Table 7 shows the alcohol content change of alcohol fermentation for four strains of Aronia yeast. In the case of alcohol content, when 0 hour of yeast fermentation was set as 0, it was confirmed that the S. cerevisiae strain made the highest alcohol content by sugar metabolism, with 3.10 ± 0.10 from 0 fermentation start to 46 hours fermentation.
아로니아 효모 4종 균주에 대한 알코올 발효의 베타글루칸 함량 변화는 표 8과 같다. 베타글루칸 함량의 경우 효모 발효 0시간을 0으로 기준으로 했을 경우 S. cerevisiae 균주는 발효 시작 0에서 발효 46시간 2.7±0.1로 효모 발효 과정의 대사물질 중 S. boulardii 균주 3.5±0.2 다음으로 가장 높게 만드는 것을 확인하였다.Table 8 shows changes in beta-glucan content of alcohol fermentation for four strains of Aronia yeast. In the case of beta-glucan content, when 0 hour of yeast fermentation was set as 0, the S. cerevisiae strain was 2.7±0.1 from fermentation start 0 to fermentation 46 hours, the highest after S. boulardii strain 3.5±0.2 among the metabolites of the yeast fermentation process. confirmed to make.
상기와 실험 결과에서 볼 수 있듯이, 효모 4종 균주 중 가장 알코올 생성에 적합한 균주를 선별하기 위해 발효 조건을 동일하게 주었을 때 효모 균주별 성분 변화를 측정한 결과 S. cerevisiae 균주가 알코올 함량 생성능 가장 높은 것으로 판단되었다. 또한, 균주 선택에 있어 알코올 결과와 효모 대사산물 결과를 비교할 때 일반 빵 효모이면서 알코올 생성 능히 우수한 S. cerevisiae 와 대사물질이 우수한 S. boulardii 균주를 택하기로 하였다.As can be seen from the above and experimental results, in order to select the strain most suitable for producing alcohol among the four strains of yeast, when the same fermentation conditions were given, the change in the components of each yeast strain was measured, and as a result, the S. cerevisiae strain had the highest alcohol content producing ability. It was judged to be In addition, when comparing the results of alcohol and yeast metabolites in the selection of strains, it was decided to select S. cerevisiae, which is a general baker's yeast and has excellent alcohol production, and S. boulardii, which has excellent metabolites.
실시예 2: 아로니아 추출물의 제조 조건 확립Example 2: Establishment of Manufacturing Conditions for Aronia Extract
2-1. 아로니아 파쇄물의 주정 농도별 함량에 따른 총당 및 환원당 함량 조사2-1. Investigation of total sugar and reducing sugar content according to alcohol concentration of aronia lysate
상기 실시예 1에서 아로니아 단순 파쇄로는 알코올 10%를 생성할 수 없음을 판단하여 아로니아 파쇄물을 주정 농도별 함량에 따라 열수 추출하여 총당 및 환원당을 비교하여 최적의 추출 조건을 찾기 위해 본 실험을 진행하였다. 총당 및 환원당 함량은 상기 실시예 1의 방법과 동일하였다. 이에 대한 결과를 표 9 및 10에 나타내었다.In Example 1, it was determined that 10% of alcohol could not be produced by simple crushing of aronia, and hot water extraction of the crushed aronia according to the content of alcohol concentration was carried out and total sugar and reducing sugar were compared to find the optimal extraction conditions. proceeded. Total sugar and reducing sugar contents were the same as in Example 1. The results for this are shown in Tables 9 and 10.
본 발명에서의 목표치는 알코올 10%이다. 주정 10%를 사용 시 총당이 13.66±0.087%를 나타내었다. 이는 타 연구 결과를 참고하였을 때 알코올 함량은 전체 당의 1/2 정도 만들어진다고 언급되어 있다. 이에 발효시간을 고려해 계산하면 알코올 10% 아로니아 파쇄물 주정 20% 추출 시 발효에 쓰이는 당인 환원당이 28%로 알코올 함량이 약 14% 만들어 내는 것으로 확인되고 있다. 이에 주정 20% 이상으로 추출하는 경우 발효 시 알코올 함량을 많이 만들 수 있다고 판단된다.The target value in the present invention is 10% alcohol. When 10% alcohol was used, total sugar was 13.66±0.087%. When referring to the results of other studies, it is mentioned that the alcohol content is about 1/2 of the total sugar. Accordingly, when calculating in consideration of the fermentation time, it is confirmed that when extracting 10% alcohol and 20% alcohol from aronia lysate, reducing sugar, the sugar used for fermentation, is 28%, and the alcohol content is about 14%. Therefore, it is judged that when extracting with 20% or more of alcohol, a large amount of alcohol can be made during fermentation.
2-2. 아로니아 파쇄물의 주정 농도별 함량에 따른 안토시아닌 함량 조사2-2. Investigation of anthocyanin content according to alcohol concentration of aronia lysate
총 안토시아닌 함량 측정을 위해 아로니아 파쇄물의 주정 농도별로 상기 2-1과 동일한 방법에 의해 추출물을 제조하고 여기에 1% HCl을 첨가한 Ethanol을 넣어 15분간 sonication 하여 안토시아닌을 추출한 후, 4000 rpm에서 10 분간 원심분리를 진행하여 얻어진 상층액을 실험에 사용하였다. 시료를 실험 농도에 맞춰 희석한 뒤, 0.025 M Potassium Chloride buffer (pH 1.0) 과 0.4M Sodium acetate buffer (pH 4.5)를 혼합한 후 15 분 동안 반응시키고 510 및 700 nm 흡광도에서 측정한 후 하기 수학식 2를 사용하여 총 안토시아닌 함량을 측정하였다. 표준물질은 최고흡광도 확인 후 측정 시 안토시아닌 람다맥스 값을 적용하였다.In order to measure the total anthocyanin content, extracts were prepared by the same method as in 2-1 for each alcohol concentration of the aronia lysate, and 1% HCl was added to the extract, and then anthocyanins were extracted by sonication for 15 minutes, followed by 10 at 4000 rpm. The supernatant obtained by centrifugation was used for the experiment. After diluting the sample according to the experimental concentration, 0.025 M Potassium Chloride buffer (pH 1.0) and 0.4M Sodium acetate buffer (pH 4.5) were mixed, reacted for 15 minutes, and measured at 510 and 700 nm absorbance, followed by the following equation 2 was used to determine the total anthocyanin content. For the standard material, the value of anthocyanin lambdamax was applied when measuring after confirming the maximum absorbance.
[수학식 2][Equation 2]
총 안토시아닌 함량(mg/gram) = (A × MW × DF × 1000) / ε × VTotal anthocyanin content (mg/gram) = (A × MW × DF × 1000) / ε × V
A (흡광도)=(A510 nm-A700 nm)pH 1.0 - (A510 nm-A700 nm)pH 4.5,A (absorbance) = (A510 nm-A700 nm)pH 1.0 - (A510 nm-A700 nm)pH 4.5;
MW (cyanidine-3-glucoside 분자량) = 322.17MW (cyanidine-3-glucoside molecular weight) = 322.17
DF: Dilutiion factorDF: dilution factor
ε(cyanidin chloride molar absorbance) = 24,600 M-1cm-1,ε(cyanidin chloride molar absorbance) = 24,600 M-1cm-1,
V = 시료 최종 부피V = final volume of sample
하기 표 11에서 볼 수 있는 바와 같이, 10%-100% 주정 추출물의 안토시아닌 함량 측정을 비교한 결과, 첫 번째 실험에서 70% 주정 추출물에서 안토시아닌 함량이 가장 높게 나타났다.As can be seen in Table 11 below, as a result of comparing the measurement of anthocyanin content of 10%-100% alcohol extract, the anthocyanin content was highest in the 70% alcohol extract in the first experiment.
(1000μg/mL)(1000μg/mL)
실시예 3: 아로니아 파쇄물의 주정 20% 추출물의 발효물에 대한 알코올 함량 등 측정Example 3: Measurement of alcohol content, etc. of fermented product of 20% alcohol extract of aronia lysate
상기 실시예 2에서 아로니아 파쇄물을 20% 주정 추출한 배지가 환원당 함량이 28%인 것을 확인하였으므로 실시예 1과 동일한 방법으로 아로니아 파쇄물의 20% 주정 추출물에 대한 pH, 산도, 아미노산도, 총당, 환원당, 생균 수 및 알코올 함량을 측정하였다. 그 결과를 하기 표 12 내지 18에 나타내었다. 한편, 본 실험에 사용한 아로니아 파쇄물의 20% 주정 출물물은 주정 추출 후 농축한 이후 상기 실험을 진행하였는데, 이는 효모발효 후 식용으로 포도주 제조를 하기 위해 주정을 날리기 위함이었다.In Example 2, it was confirmed that the medium in which 20% alcohol was extracted from the aronia lysate had a reducing sugar content of 28%, so pH, acidity, amino acid level, total sugar, Reducing sugar, viable cell count and alcohol content were measured. The results are shown in Tables 12 to 18 below. On the other hand, the 20% alcohol extract of the aronia lysate used in this experiment was concentrated after alcohol extraction, and then the experiment was conducted, which was to blow alcohol to produce wine for food after yeast fermentation.
상기 표 12 내지 18에서 볼 수 있는 바와 같이, 주정 20% 주정 추출물을 사용 시 아로니아 발효물의 알코올 생성능이 증가하는 것을 확인할 수 있었으나 본 발명의 하나의 목적인 알코올 함량 10%에는 못 미치는 것을 확인할 수 있었다. 이에 다음 실험에서는 보당을 하되 보당 설탕을 사용하지 않고 배 농축액을 사용하고자 하였다. 또한 이후 실험에서는 상기 실시예 2-2의 안토시아닌 함량을 고려하여 주정 70%를 사용하였다.As can be seen in Tables 12 to 18, it was confirmed that the alcohol-producing ability of the fermented aronia increased when the 20% alcohol extract was used, but it was confirmed that the alcohol content of 10%, which is one purpose of the present invention, was not reached . Therefore, in the next experiment, we tried to use pear concentrate without using supplement sugar, but supplement sugar. Also, in subsequent experiments, 70% alcohol was used in consideration of the anthocyanin content of Example 2-2.
실시예 4: 보당 함량에 따른 발효물의 알코올 함량 등 측정Example 4: Measurement of alcohol content of fermented product according to sugar content
㈜ 목사골 아로니아 연구회에서 판매하는 천수 100세 아로니아 제품 5 kg를 구매하여 사용하였으며, 발효에 사용되는 파쇄액은 1차적으로 아로니아의 가지와 열매를 분리하는 작업을 하였다. 이후 수돗물에서 열매를 세척 하였다. 세척한 열매를 블렌더(Mufti Quick 7-MQ736, ㈜ BRAUN, Germany)로 파쇄하였다. 이후 주정 70% 조건 (아로니아 파쇄물 40g + 주정 800g)으로 100°C 3시간 열수 추출 후 주정을 날리기 위해 45°C, 70~80 RPM, 80mbar 조건으로 3시간 아로니아 파쇄물을 농축하였다. 이후 이 아로니아 파쇄물을 배지로 사용하였으며 배 농축액은 총당 65.21±3.24%, 환원당 44.02±4.14%인 원료를 사용하였다. 농축된 아로니아 파쇄물에 전체 부피의 1중량% 또는 2중량%를 배 농축액으로 첨가한 후 121℃에서 15분간 살균 후 2시간 방냉 하였다. 상기 실시예 1 등과 같이 효모균 4종을 배지 부피의 0.1% 접종하여 140rpm에서 27℃에서 44~46시간 동안 배양하였다. 배양 후 아로니아 파쇄물의 주정 추출물의 발효 특성을 실시예 1에 기술된 방법과 동일한 방법으로 분석하고 그 결과로서 하기 표 19 내지 26에 1중량% 배 농축액을 혼합한 경우의 결과를, 하기 표 27내지 표 34에 2중량% 배 농축액을 혼합한 경우의 결과를 나타내었다.5 kg of 100-year-old aronia products sold by the Mokggol Aronia Research Association were purchased and used, and the lysate used for fermentation was primarily used to separate the branches and fruits of aronia. Afterwards, the fruits were washed in tap water. The washed fruit was crushed with a blender (Mufti Quick 7-MQ736, BRAUN, Germany). Then, after hot water extraction at 100 ° C for 3 hours under the condition of 70% alcohol (40 g of aronia lysate + 800 g of alcohol), the aronia lysate was concentrated for 3 hours under the conditions of 45 ° C, 70 ~ 80 RPM, 80 mbar to blow the alcohol. Afterwards, this aronia lysate was used as a medium, and pear concentrate was used as a raw material with 65.21 ± 3.24% of total sugar and 44.02 ± 4.14% of reducing sugar. After adding 1% by weight or 2% by weight of the total volume to the concentrated aronia lysate as a pear concentrate, sterilization at 121 ° C. for 15 minutes, followed by cooling for 2 hours. As in Example 1, four types of yeast were inoculated at 0.1% of the medium volume and cultured at 140 rpm and 27 ° C for 44 to 46 hours. After cultivation, the fermentation characteristics of the alcohol extract of the aronia lysate were analyzed by the same method as that described in Example 1, and as a result, the results of mixing 1% by weight pear concentrate in Tables 19 to 26 below are shown in Table 27 below. To Table 34 shows the results when 2% by weight pear concentrate was mixed.
상기 표 19 내지 34에서 볼 수 있는 바와 같이, 70 % 주정 추출물에 배 농축액 1중량% 첨가하는 경우보다 배 농축액 2중량% 첨가하는 경우에 발효물의 알코올 함량이 10% 이상인 것을 확인할 수 있었다. 특히, S. cerevisiae 균주의 경우에 S. boulardii 균주보다 알코올 함량이 더 높았으나 효모 대사산물 중 하나인 베타글루칸의 함량은 S. boulardii 균주가 S. cerevisiae 균주보다 더 높았음을 확인할 수 있었다.As can be seen in Tables 19 to 34, it was confirmed that the alcohol content of the fermented product was 10% or more when 2% by weight of the pear concentrate was added compared to the case where 1% by weight of the pear concentrate was added to the 70% alcohol extract. In particular, in the case of the S. cerevisiae strain, the alcohol content was higher than that of the S. boulardii strain, but the content of beta-glucan, one of the yeast metabolites, was confirmed to be higher in the S. boulardii strain than in the S. cerevisiae strain.
이후 다음 실험은 배 농축액 2%로 보당 한 후 S. cerevisiae 균주와 S. boulardii 균주를 최적 균주로 택한 후 실험을 진행하였다.Afterwards, the next experiment was carried out after supplementing with 2% pear concentrate and selecting S. cerevisiae and S. boulardii strains as the optimal strains.
실시예 5: 발효 시간에 따른 발효물의 알코올 함량 등 측정Example 5: Measurement of alcohol content of fermented product according to fermentation time
㈜목사골 아로니아 연구회에서 판매하는 천수 100세 아로니아 제품 5 kg를 구매하여 사용하였으며, 발효에 사용되는 파쇄액은 1차적으로 아로니아의 가지와 열매를 분리하는 작업을 하였다. 이후 수돗물에서 열매를 세척 하였다. 세척한 열매를 블렌더(Mufti Quick 7-MQ736, ㈜ BRAUN, Germany)로 파쇄하였다. 이후 앞선 보당 실험을 통해 확인하였던 주정 70% 조건 (아로니아 파쇄물 40g + 주정 800g)으로 100°C 3시간 열수 추출 후 주정을 날리기 위해 45°C, 70~80 RPM, 80mbar 조건으로 3시간 아로니아 파쇄물을 농축하였다. 이후 이 아로니아 파쇄물을 배지로 사용하였으며 배 농축액은 총당 65.21±3.24%, 환원당 44.02±4.14%인 원료를 사용하였다. 농축된 아로니아 파쇄물에 전체 부피의 2%를 배 농축액으로 첨가하였다. 본 실험은 5L fermenter (KB -250, ㈜ KO Biotech, Incheon, Korea) 으로 실험을 진행하였으며 실험 배지의 부피는 최소 3.5 L로 진행하였다. fermented에 배지를 제조 후 121℃에서 15분간 살균 후 3시간 방냉 하였다. 이후 Saccharomyces cerevisiae (KCTC NO. 27756) 및 Saccharomyces boulardii srcnm 001 2종을 배지 부피의 0.1% 접종하여 120rpm, 산소통기량인 VVM 0.2 에서 27℃에서 44시간 또는 72시간 동안 배양하였다.5 kg of 100-year-old aronia products sold by the Moksagol Aronia Research Society were purchased and used, and the lysate used for fermentation was primarily separated from the branches and fruits of aronia. Afterwards, the fruit was washed in tap water. The washed fruit was crushed with a blender (Mufti Quick 7-MQ736, BRAUN, Germany). Then, hot water extraction at 100°C for 3 hours under the condition of 70% alcohol (40g of aronia lysate + 800g of alcohol), which was confirmed through the previous supplement experiment, followed by 3 hours of aronia at 45°C, 70-80 RPM, 80mbar to blow off the alcohol. The lysate was concentrated. Afterwards, this aronia lysate was used as a medium, and pear concentrate was used as a raw material with 65.21 ± 3.24% of total sugar and 44.02 ± 4.14% of reducing sugar. 2% of the total volume was added as pear concentrate to the concentrated aronia lysate. This experiment was conducted with a 5L fermenter (KB -250, KO Biotech Co., Ltd., Incheon, Korea), and the volume of the experiment medium was at least 3.5 L. After preparing the fermented medium, it was sterilized at 121 ° C for 15 minutes and allowed to cool for 3 hours. Thereafter, Saccharomyces cerevisiae (KCTC NO. 27756) and Saccharomyces boulardii srcnm 001 were inoculated at 0.1% of the volume of the medium and cultured at 27° C. for 44 hours or 72 hours at 120 rpm and oxygen aeration rate of VVM 0.2.
배양 후 아로니아 파쇄물의 주정 추출물의 발효 시간에 따른 발효 특성을 실시예 1에 기술된 방법과 동일한 방법으로 분석하고 그 결과로서 하기 표 35 내지 44에 발효시간이 44시간인 경우의 결과를, 하기 표 45 내지 표 54에 2중량% 발효시간이 72시간인 경우의 결과를 나타내었다.After cultivation, the fermentation characteristics according to the fermentation time of the alcohol extract of the aronia lysate were analyzed by the same method as described in Example 1, and as a result, the results when the fermentation time was 44 hours in Tables 35 to 44 below, Tables 45 to 54 show the results when the 2% by weight fermentation time was 72 hours.
상기 결과에서 볼 수 있는 바와 같이, 5L fermented로 72시간 및 44시간 비교실험을 한 결과 효모 대사산물로 봤을 때 44시간 발효시간보다 72시간 발효시간이 우수하다는 것을 확인할 수 있었으며 알코올 함량도 발효시간을 24시간 증가에 따라 증가하는 것을 확인할 수 있었다. 이에 이후 초산발효를 위해서는 알코올 함량이 높은 것이 유리하므로 발효 72시간이 최적이라고 판단되었다.As can be seen from the above results, as a result of a comparative experiment of 72 hours and 44 hours with 5L fermented, it was confirmed that the 72-hour fermentation time was superior to the 44-hour fermentation time in terms of yeast metabolites, and the alcohol content also increased the fermentation time. It was confirmed that it increased with the increase of 24 hours. Therefore, since a high alcohol content is advantageous for acetic acid fermentation, it was determined that 72 hours of fermentation was optimal.
실시예 6: 발효물의 알코올 생성 및 초산 발효 실험Example 6: Experiments on alcohol production and acetic acid fermentation of fermented products
상기 실시예 5의 실험 방법과 동일하게 아로니아 파쇄물 (주정 70% 추출 용액) 및 배 농축액 2중량%를 혼합한 후 72시간 동안 효모 배양하였으며, 그 효모 배양된 아로니아 발효물을 1차 부직포 필터 및 2차 페이퍼 필터를 한 후 다시 jar fermenter에 넣은 후 아세토박터 아세티(Acetobacter aceti (ATCC15973))를 전체 부피의 1% 접종 후 7일간 초산 발효하였다. 그 초산 발효물에 대하여 상기 실시예 1과 동일한 방법으로 분석을 수행하였고, 그 결과를 하기 표 55 내지 59에 나타내었다.In the same way as in Example 5, after mixing the aronia lysate (70% alcohol extraction solution) and 2% by weight of the pear concentrate, the yeast was cultured for 72 hours, and the yeast cultured aronia fermented product was filtered through a primary non-woven fabric. And after a second paper filter, it was put back into the jar fermenter, and Acetobacter aceti (ATCC15973) was inoculated at 1% of the total volume, followed by acetic acid fermentation for 7 days. The acetic acid fermented product was analyzed in the same manner as in Example 1, and the results are shown in Tables 55 to 59 below.
상기 결과에서 볼 수 있듯이, 효모에 따라 초산 생성양이 유의적으로 차이가 있음을 확인할 수 있었다. 또한 대사산물인 베타글루칸이 많이 만들어지는 S. boulardii 균주의 경우 초산발효를 함에 따라 S. cerevisiae 균주보다 감소폭이 적은 것을 확인할 수 있었다. 이에 사용 및 목적에 따라 두 균주가 모두 최적조건이라고 판단된다. 식초 및 초산의 양을 증가하고자 하면 S. cerevisiae 균주로 효모발효를 한 후 초산발효가 최적조건이고, 대사산물을 원한다 하면 S. boulardii 균주로 효모발효를 한후 초산발효를 하는게 최적조건이라고 판단된다.As can be seen from the above results, it was confirmed that there was a significant difference in the amount of acetic acid produced depending on the yeast. In addition, in the case of the S. boulardii strain, which produces a large amount of metabolite beta-glucan, it was confirmed that the decrease was smaller than that of the S. cerevisiae strain by acetic acid fermentation. Accordingly, it is determined that both strains are optimal conditions depending on use and purpose. To increase the amount of vinegar and acetic acid, yeast fermentation with S. cerevisiae strain followed by acetic acid fermentation is the optimal condition, and if metabolites are desired, yeast fermentation with S. boulardii strain followed by acetic acid fermentation is considered the optimal condition.
실시예 7: 산업적 효모 발효 및 오크통 숙성 실험Example 7: Industrial yeast fermentation and oak barrel aging experiments
대량 생산을 위한 산업적 효모 발효의 적합성을 확인하기 위하여 실험을 진행하였다. 대형 알코올 발효통의 RPM 특성을 고려하여 아로니아 파쇄물의 주정 70% 추출물과 배 농축액 2%의 혼합물을 5%로 설정하여 첨가하였다. 오크통은 1일 주기로 정제수를 교환해주며 5일간 불림처리를 하며 완료 후 잡균의 생육을 억제하기 위해 아황산나트륨(1g/1L)으로 내부소독을 진행하였다. 발효가 완료된 아로니아 발효액은 오크통으로 이동하여 6 ℃에서 2개월간 숙성을 진행하였다.An experiment was conducted to confirm the suitability of industrial yeast fermentation for mass production. A mixture of 70% alcohol extract and 2% pear concentrate of aronia lysate was added by setting it to 5% in consideration of the RPM characteristics of a large alcohol fermenter. The oak barrel was soaked for 5 days while exchanging purified water on a daily cycle, and after completion, internal disinfection was carried out with sodium sulfite (1g/1L) to suppress the growth of germs. Fermented aronia fermented liquid was moved to an oak barrel and aged at 6 ° C for 2 months.
산업적으로 발효된 아로니아 발효액은 본 명세서에 기재하지 않았지만 상기 실시예 6의 결과와 유사하게 나타났다.The industrially fermented aronia fermentation broth was similar to the results of Example 6, although not described herein.
또한, 산업적으로 발효된 아로니아 발효액을 오크통으로 이동한 후 숙성 전, 숙성 1개월 경과 후, 및 숙성 2개월 경과 후의 산도, pH, Brix 함량, 및 알코올 함량을 상기 실시예 1과 동일한 방법으로 측정하였다.In addition, after moving the industrially fermented aronia fermented liquid into an oak barrel, the acidity, pH, Brix content, and alcohol content before aging, after 1 month of aging, and after 2 months of aging were measured in the same manner as in Example 1. did
그 결과로서, 산도의 경우 숙성 전 1.55~1.57%로 나타났으며 숙성 1달의 산도는 Oak-1, Oack-2 각각 1.52%, 1.57% 숙성 2달의 산도는 1.50%, 1.55%로 나타났다. 산도(%)의 경우 숙성 2달까지 일정하게 유지 되는 것으로 나타났다. pH의 경우 숙성 전 3.936~4.001의 수치를 나타내었으며 숙성 2달에서 4.014~4.045로 pH 수치가 약간 증가하는 경향을 보였으나 큰 차이는 없는 것으로 나타났다.As a result, the acidity was 1.55~1.57% before aging, and the acidity of 1 month of aging was 1.52% and 1.57% of Oak-1 and Oak-2, respectively, and the acidity of 2 months of aging was 1.50% and 1.55%. In the case of acidity (%), it was found that it was kept constant until 2 months of aging. In the case of pH, the value was 3.936 to 4.001 before aging, and the pH value slightly increased to 4.014 to 4.045 after 2 months of aging, but there was no significant difference.
Brix 함량의 경우 숙성 전 Oak-1, Oak-2 각각 17.0%, 17.5%로 산업적 대형효모발효의 당도 %와 일치하였고 숙성 2달차에서 각각 16.8%, 17.4%로 약간 감소하나 수치상 큰 차이는 없었으나 숙성이 더욱 지속될수록 당도함량은 감소할 것이라 생각된다.In the case of Brix content, before aging, Oak-1 and Oak-2 were 17.0% and 17.5%, respectively, consistent with the % sugar content of industrial large-scale yeast fermentation. It is thought that the longer the aging, the lower the sugar content.
알코올 함량의 경우 숙성이 진행될수록 알코올의 함량은 증가하는 경향으로 나타났다. 숙성 2달차에서의 알코올 함량은 Oak-1, Oak-2 각각 10.5%, 11.0%까지 증가하였으며 저온환경과 오크통의 영향의 의한 후발효가 지속적으로 진행되어 지는 것으로 사료된다.In the case of alcohol content, the alcohol content tended to increase as aging progressed. The alcohol content in the 2nd month of aging increased to 10.5% and 11.0% in Oak-1 and Oak-2, respectively, and it is thought that post-fermentation is continuously progressing due to the influence of low-temperature environment and oak barrel.
실시예 8: 아로니아 최적 초산발효물의 대량 생산공정 확립Example 8: Establishment of mass production process for optimal acetic acid fermentation of aronia
8-1. 아로니아 최적 초산발효 공정 확립8-1. Establishment of optimal acetic acid fermentation process for aronia
아로니아 초산발효 공정의 최적 조건을 확인하기 위하여 ㈜코바이오텍의 5L Jar fermentor를 사용하여 진행하였다. Jar fermentor의 발효 진행 시간에 따라 총산도, pH, 당도(brix%), 알코올함량(%), DO, BOD를 하기 분석 방법으로 측정하였다. 초산 발효는 상기 실시예 등에 기술된 아로니아 효모(S. cerevisiae) 발효액을 사용하여 종초를 첨가한 후 초기 산도를 1.5~2.0%로 보정한 뒤 통기량 VVM 0.5, 250 rpm, 30℃로 발효조건을 설정하여 14일간 호기성 발효를 진행하였다. 그 구체적인 공정을 도 1에 나타내었다.In order to confirm the optimal conditions of the aronia acetic acid fermentation process, it was carried out using a 5L Jar fermentor from Kobiotech Co., Ltd. Total acidity, pH, sugar content (brix%), alcohol content (%), DO, and BOD were measured according to the fermentation progress time of the Jar fermentor by the following analysis method. Acetic acid fermentation uses the aronia yeast (S. cerevisiae) fermentation liquid described in the above examples, etc., after adding seeds, correcting the initial acidity to 1.5 ~ 2.0%, and then fermenting conditions at aeration rate VVM 0.5, 250 rpm, 30 ℃ was set to proceed with aerobic fermentation for 14 days. The specific process is shown in Figure 1.
분석 방법analysis method
1) 총산 및 pH측정 1) Measurement of total acid and pH
총산 함량은 초산 발효 기간 중 시료를 원심분리 후 상층액 1 mL를 취해 1% Phenolphthalein을 지시약으로 하여 0.1 N NaOH 용액으로 중화 적정하고 acetic acid 환산 계수로 계산하여 산도(%)를 나타내었다(수학식 3 참조). 발효물의 pH는 시료 20 mL를 취해 pH meter (SevenEasy, Mettler-Toledo AG, Schwerzenbach, Switzerland)를 이용하여 측정한다.For the total acid content, after centrifuging the sample during the acetic acid fermentation period, 1 mL of the supernatant was taken, neutralized and titrated with 0.1 N NaOH solution using 1% Phenolphthalein as an indicator, and acidity (%) was shown by calculating with an acetic acid conversion factor (Equation see 3). The pH of the fermentation product was measured by taking a 20 mL sample and using a pH meter (SevenEasy, Mettler-Toledo AG, Schwerzenbach, Switzerland).
[수학식 3][Equation 3]
총산(Acidity, %) = [(0.1N-NaOH Consumption × 0.006g × F) / Sample volume] (mL) ×100Total Acidity (%) = [(0.1N-NaOH Consumption × 0.006g × F) / Sample volume] (mL) × 100
F : 0.1N-NaOH factorF: 0.1N-NaOH factor
2) Brix (Soluble solid content) 함량 측정2) Brix (Soluble solid content) content measurement
당도는 발효물 500 μL를 취해 당도계 (ATAGO, Pocket Refractometer, P AL-2)를 이용하여 측정하였다.Sugar content was measured using a sugar meter (ATAGO, Pocket Refractometer, P AL-2) by taking 500 μL of the fermented product.
3) 알코올 함량 측정3) Alcohol content measurement
알코올 함량 측정은 국세청 주류분석규정에 따라 측정하였다. 메스실린더에 발효물 100 mL를 취한 후 둥근 플라스크에 옮겼다. 발효물이 넣어져 있던 메스실린더를 증류수 10 mL로 3회 이상 씻은 후 그 액을 합쳤다. Soxhlet heater를 이용하여 발효물이 들어있는 둥근 플라스크에 열을 가하여 증류하였다. 증류액이 70 mL가 되면 증류를 정지하고 증류수를 보충하여 100 mL가 되도록 하였다. 이후 교반하여 주정계 (ATAGO, PAL-2REFRACTOMETER)를 이용하여 알코올 함량을 나타내었다.Alcohol content was measured according to the National Tax Service's liquor analysis regulations. After taking 100 mL of the fermentation product in a measuring cylinder, it was transferred to a round flask. After washing the measuring cylinder containing the fermented product three or more times with 10 mL of distilled water, the solutions were combined. Heat was applied to the round flask containing the fermented product using a Soxhlet heater to distill it. When the distillate reached 70 mL, distillation was stopped and distilled water was replenished to make 100 mL. After stirring, the alcohol content was indicated using a spirit meter (ATAGO, PAL-2REFRACTOMETER).
4) DO 및 BOD 측정4) DO and BOD measurement
발효액의 용존산소량 및 생물화학적 산소요구량 측정은 (DO-31P, ㈜ TOADKK, Tokyo, Japan)를 이용하여 측정하였다. 발효액 15 mL 정량하여 용존산소량을 측정하며, 발효 0일 차의 용존산소량은 100%, 생물학적 산소요구량은 0%로 환산하여 산출하였다.The amount of dissolved oxygen and biochemical oxygen demand of the fermentation broth were measured using (DO-31P, TOADKK Co., Ltd., Tokyo, Japan). The amount of dissolved oxygen was measured by quantifying 15 mL of the fermentation broth, and the amount of dissolved oxygen on the 0th day of fermentation was converted into 100% and the biological oxygen demand was calculated as 0%.
분석 결과Analysis
1) 총산 및 pH측정 1) Measurement of total acid and pH
아로니아 효모 발효물(와인)을 이용한 초산발효의 기간에 따른 산도와 pH 변화는 표 60 및 61과 같다. 초산발효 개시 전 AAF-0.5 시료군의 초기 산도는 1.78%로 나타났다. 산도변화는 발효 8일까지 2.13%로 약 0.4%만큼 증가하였으나 발효 14일에서 산도 4.14%로 급격하게 증가하였다. pH의 경우 초산발효가 진행됨에 따라 수치가 낮아지는 것을 확인하였으며 초기 3.87에서 초산발효 종료 후 3.60로 나타났다. Acidity and pH changes according to the period of acetic acid fermentation using Aronia yeast fermentation product (wine) are shown in Tables 60 and 61. The initial acidity of the AAF-0.5 sample group before the start of acetic acid fermentation was 1.78%. The acidity change increased by about 0.4% to 2.13% until the 8th day of fermentation, but it increased rapidly to 4.14% on the 14th day of fermentation. In the case of pH, it was confirmed that the value decreased as the acetic acid fermentation progressed, and it was found to be 3.60 after the acetic acid fermentation was completed from 3.87 at the beginning.
2) Brix (Soluble solid content) 함량 측정2) Brix (Soluble solid content) content measurement
아로니아 와인을 이용한 초산발효의 기간에 따른 당도 변화는 표 62와 같다. 발효 초기 0일의 당도는 16.1%로 나타났으며 초산발효가 진행됨에 따라 서서히 감소하는 경향으로 나타났다. 이는 당도가 초기 발효에 필요한 탄소원으로서 초산발효에 작용하는 것으로 판단되며 발효 4일차에서 15.1%, 8일 14.5%로 나타났고 발효종료 14일에서는 14.5%로 발효 8일차와 동일하게 나타났다.Table 62 shows the change in sugar content according to the period of acetic acid fermentation using Aronia wine. The sugar content on day 0 of the initial fermentation was 16.1% and gradually decreased as acetic acid fermentation progressed. It is judged that sugar content acts on acetic acid fermentation as a carbon source necessary for initial fermentation, and it was 15.1% on the 4th day of fermentation and 14.5% on the 8th day, and 14.5% on the 14th day after fermentation was completed, which was the same as the 8th day of fermentation.
3) 알코올 함량 측정3) Alcohol content measurement
아로니아 와인을 이용한 초산발효의 기간에 따른 알코올 변화는 표 63과 같다. 알코올 성분은 발효를 통해 초산으로 전환되는 물질이며 일반적으로 초산발효가 진행됨에 있어 알코올 함량은 4~8%로 보고되어 진다. AAF-0.5 시료군의 초기 알코올 함량은 8.2%로 나타났고 발효 4일에서 4.0%, 발효 8일에서 1.7%까지 감소하였으며 발효종료 14일의 알코올함량은 0.5%로 나타났다.Table 63 shows the alcohol change according to the period of acetic acid fermentation using Aronia wine. The alcohol component is a substance that is converted into acetic acid through fermentation, and in general, as acetic acid fermentation proceeds, the alcohol content is reported to be 4-8%. The initial alcohol content of the AAF-0.5 sample group was 8.2%, decreased to 4.0% on the 4th day of fermentation and 1.7% on the 8th day of fermentation, and the alcohol content on the 14th day of fermentation was 0.5%.
4) DO, BOD 측정4) DO, BOD measurement
아로니아 와인(발효물)을 이용한 초산발효의 기간에 따른 DO 및 BOD 변화는 표 64 및 65와 같다. 초산균은 초기성장기에서 빠른 성장과 원활한 대사를 위해 많은 산소를 요구한다. 또한 미생물의 성장 정지와 사멸기에 접어들어 생균수가 감소함에 따라 용존산소량은 증가하게 된다. 통기량은 VVM 0.5 설정하였으며, 발효 0시간에서 용존산소량과 생화학적 산소요구량은 각각 100%, 0%으로 환산하여 나타내었다. 초산발효 4일차에서 AAF-0.5의 용존 산소량은 73.5%로 생화학적 산소요구량은 26.5%로 나타났으며, 초산발효가 진행됨에 따라 용존산소량은 감소하여 발효 14일에서 1.2%로 나타난 반면 생화학적 산소요구량의 경우 98.8%까지 증가하는 경향으로 나타났다.Changes in DO and BOD according to the period of acetic acid fermentation using aronia wine (fermented product) are shown in Tables 64 and 65. Acetic acid bacteria require a lot of oxygen for rapid growth and smooth metabolism in the early growth phase. In addition, the amount of dissolved oxygen increases as the number of viable cells decreases as the growth of microorganisms enters the stage of cessation and death. The amount of aeration was set at VVM 0.5, and the amount of dissolved oxygen and biochemical oxygen demand at 0 hour of fermentation were converted to 100% and 0%, respectively. On the 4th day of acetic acid fermentation, the amount of dissolved oxygen in AAF-0.5 was 73.5%, and the biochemical oxygen demand was 26.5%. In the case of demand, it showed a tendency to increase up to 98.8%.
8-2. 아로니아 최적 초산발효 공정 확립8-2. Establishment of optimal acetic acid fermentation process for aronia
상기 실시예 8-1의 Jar fermentor를 이용한 초산발효 종료 후 대량생산을 위한 산업적 초산발효를 진행하였다. 발효조건 중 온도 30℃를 제외한 나머지 대형 발효통의 RPM 특성과 발효기환경을 고려하여 1일당 1시간씩 air 주입을 진행하였다. 초산발효가 종료된 발효액은 산업용 연속원심분리기를 이용하여 아로니아 발효 부산물과 발효액을 분리하였다. 분리된 부산물은 열풍건조를 진행하여 분말화를 진행하였다.After the acetic acid fermentation using the Jar fermentor of Example 8-1 was completed, industrial acetic acid fermentation for mass production was performed. Among the fermentation conditions, air injection was performed for 1 hour per day in consideration of the RPM characteristics of the large fermentation vats and the fermenter environment, except for the temperature of 30 ° C. The fermented liquid after the acetic acid fermentation was separated from the fermented liquid by-product of the aronia fermentation using an industrial continuous centrifugal separator. The separated by-product was powdered by hot air drying.
상기 제조된 아로니아 발효 부산물의 발효 진행 시간에 따른 총산도, pH, 당도(brix%), 알코올함량(%), DO, BOD를 상기 실시예 8-1의 분석 방법으로 측정하고 그 결과를 하기 표 65 내지 68에 나타내었다.Total acidity, pH, sugar content (brix%), alcohol content (%), DO, and BOD according to the fermentation progress time of the prepared aronia fermentation by-product were measured by the analysis method of Example 8-1, and the results are as follows Tables 65 to 68 show.
1) 총산 및 pH측정 1) Measurement of total acid and pH
아로니아 와인(발효물)을 이용한 산업적 초산발효의 기간에 따른 산도와 pH 변화는 표 66 및 67과 같다. 시료는 0일, 4일, 8일, 14일 간격으로 시료를 채취하여 측정하였으며 초산발효 개시 전 BAF-1의 초기 산도는 1.79%로 나타났다. 산도 변화는 발효 8일까지 3.08%로 증가하여 발효 14일에서 산도 4.20%로 초기산도보다 약 46.61%의 초산수율이 증가하는 것으로 나타났다. pH의 경우 초산발효가 진행됨에 따라 수치가 낮아지는 것을 확인하였으며 초기 pH 4.01에서 초산발효 종료 후 pH 3.61로 나타났다.Changes in acidity and pH according to the period of industrial acetic acid fermentation using aronia wine (fermented product) are shown in Tables 66 and 67. Samples were collected and measured at intervals of 0, 4, 8, and 14 days, and the initial acidity of BAF-1 before the start of acetic acid fermentation was 1.79%. The change in acidity increased to 3.08% by the 8th day of fermentation, and by the 14th day of fermentation, the acidity was 4.20%, indicating that the acetic acid yield increased by about 46.61% compared to the initial acidity. In the case of pH, it was confirmed that the value decreased as the acetic acid fermentation proceeded, and the pH was 3.61 after the acetic acid fermentation was completed from the initial pH of 4.01.
2) Brix (Soluble solid content) 함량 측정2) Brix (Soluble solid content) content measurement
아로니아 와인을 이용한 산업적 초산발효의 기간에 따른 당도 변화는 표 68과 같다. 발효 초기 0일의 당도는 16.7%로 나타났으며, 초산발효가 진행됨에 따라 지속적으로 감소하여 발효 4일 14.8%, 발효 8일 13.9%, 발효 14일 13.2%로 나타났다. 상기 실시예 8-1의 Lab scale에서 진행되었던 당도 변화의 경향과 동일한 패턴을 나타내었다.Table 68 shows the change in sugar content according to the period of industrial acetic acid fermentation using Aronia wine. The sugar content on the initial day 0 of fermentation was 16.7%, and it decreased continuously as acetic acid fermentation progressed to 14.8% on the 4th day of fermentation, 13.9% on the 8th day of fermentation, and 13.2% on the 14th day of fermentation. It showed the same pattern as the trend of sugar content change that proceeded on the Lab scale of Example 8-1.
3) 알코올 함량 측정3) Alcohol content measurement
아로니아 와인을 이용한 산업적 초산발효의 기간에 따른 알코올 변화는 표 69와 같다. 알코올 성분은 발효를 통해 초산으로 전환되는 물질이며 일반적으로 초산발효가 진행됨에 있어 알코올 함량은 4~8%로 보고되어 진다. BAF-1 시료군의 초기 알코올 함량은 8.0%로 나타났고 발효 4일에서 6.2%, 발효 8일에서 3.5%까지 감소하였다. 알코올 함량 또한 상기 실시예 8-1의 Lab scale에서의 알코올 함량 변화와 동일하게 감소하는 패턴을 나타내었으나 발효종료 14일의 알코올함량은 1.83%로 나타났다. 이는 Jar fermentor와 다르게 발효기기 형상에 의한 air 주입의 차이로 사료된다.Table 69 shows the alcohol change according to the period of industrial acetic acid fermentation using Aronia wine. The alcohol component is a substance that is converted into acetic acid through fermentation, and in general, as acetic acid fermentation proceeds, the alcohol content is reported to be 4-8%. The initial alcohol content of the BAF-1 sample group was 8.0% and decreased to 6.2% on the 4th day of fermentation and to 3.5% on the 8th day of fermentation. The alcohol content also showed the same decreasing pattern as the alcohol content change on the Lab scale of Example 8-1, but the alcohol content on the 14th day after fermentation was terminated was 1.83%. This is considered to be the difference in air injection due to the shape of the fermentation device, unlike the Jar fermentor.
실시예 9: 아로니아 식초의 항염증 검정Example 9: Anti-inflammatory assay of aronia vinegar
9-1. 아로니아 식초의 세포독성 검정9-1. Cytotoxicity assay of aronia vinegar
실험에 사용한 대식세포주인 RAW 264.7 세포는 한국세포주은행에서 분양받아 10% FBS (fetalbovine serum), 1% 항생제, 2-ME (2-mercaptoethanol)를 함유한 RPMI 1640배지를 이용하여 37℃, 4% CO2에서 조절된 incubator에서 배양하였다.RAW 264.7 cells, a macrophage cell line used in the experiment, were purchased from the Korea Cell Line Bank and cultured in RPMI 1640 medium containing 10% FBS (fetalbovine serum), 1% antibiotics, and 2-ME (2-mercaptoethanol) at 37°C and 4% It was cultured in an incubator controlled under CO2.
상기 배양한 마우스의 대식세포주 (RAW264.7)를 96 well plate에 well당 5X104 cells/100 μl씩 분주한 뒤, overnight 하였다. LPS를 1μg/ml 농도로 처리한 후 1시간 뒤, 준비한 시료를 농도별로 처리하고 24시간 동안 CO2 incubation 하였다. 그 다음 배양 상층액을 제거하고, CCK-8 시약을 처리하여 Microplate reader기를 이용하여 450nm에서 흡광도를 측정하였다.The cultured mouse macrophage cell line (RAW264.7) was dispensed per well at 5X10 4 cells/100 μl in a 96 well plate, followed by overnight. After 1 hour after treatment with LPS at a concentration of 1 μg/ml, the prepared samples were treated by concentration and subjected to CO 2 incubation for 24 hours. Then, the culture supernatant was removed, treated with CCK-8 reagent, and absorbance was measured at 450 nm using a Microplate reader.
그 결과, 도 2에서 볼 수 있는 바와 같이, 실험에 사용한 농도에서 세포 독성이 없는 것을 확인하였다(도 2).As a result, as can be seen in Figure 2, it was confirmed that there was no cytotoxicity at the concentration used in the experiment (Figure 2).
9-2. 아로니아 식초의 NO 활성 억제 효과 검정9-2. Test of NO activity inhibitory effect of aronia vinegar
대식세포에서는 LPS와 같은 외부 자극 등에 의해 염증반응이 일어나면 NO를 분비하고 염증성 cytokine과 같은 다양한 물질을 생성하고, 염증반응을 조절하는 다양한 병리적인 반응이 일어난다. LPS로 염증반응을 유도한 RAW264.7 세포에서 실험시료를 처리하여 항염증 효능을 조사하였다.In macrophages, when an inflammatory response occurs due to external stimuli such as LPS, NO is secreted, various substances such as inflammatory cytokines are produced, and various pathological responses that control the inflammatory response occur. Experimental samples were treated in RAW264.7 cells, in which an inflammatory response was induced by LPS, and anti-inflammatory efficacy was investigated.
구체적으로, 안정화된 NO 산화물인 NO2 (Nitrite)는 Griess 반응을 이용하여 측정하였다. 먼저 RAW264.7 세포를 96 well plate에 well당 5X104 cells/100 μl씩 분주한 뒤, overnight 하였다. LPS를 1μg/ml 농도로 처리하고 1시간 CO₂ incubation 한 뒤 준비한 시료를 농도별로 처리하여 24시간 CO₂ incubation 하였다. 그 다음 배양 상층액을 96 well plate에 넣고 여기에 동량의 Griess 시약 (0.1% N-1-naphtyl-ethylendiamine in H2O : 1% sulfanilamide in 5% H3PO4 = 1 : 1)을 첨가하여 10분간 반응시킨 후, Microplate reader로 550nm에서 흡광도를 측정하였다.Specifically, NO 2 (Nitrite), a stabilized NO oxide, was measured using the Griess reaction. First, RAW264.7 cells were dispensed in 5X10 4 cells/100 μl per well in a 96 well plate, followed by overnight. After treating LPS at a concentration of 1μg/ml and CO₂ incubation for 1 hour, the prepared samples were treated by concentration and CO₂ incubation was performed for 24 hours. Then, the culture supernatant was placed in a 96 well plate, and the same amount of Griess reagent (0.1% N-1-naphtyl-ethylendiamine in H 2 O : 1% sulfanilamide in 5% H 3 PO 4 = 1 : 1) was added to the mixture. After reacting for 10 minutes, absorbance was measured at 550 nm using a Microplate reader.
도 3에서 볼 수 있는 바와 같이, 아로니아 식초와 아로니아 식초 부산물은 각각 약 21%, 14%의 NO 생성 억제율을 나타내었으며, 아로니아 식초가 아로니아 식초 부산물에 비하여 NO 생성 억제율이 우수하였다.As can be seen in Figure 3, aronia vinegar and aronia vinegar by-products showed NO production inhibition rates of about 21% and 14%, respectively, and aronia vinegar was superior to aronia vinegar by-products in NO production inhibition rate.
9-3. Cytokine 생성량 검정9-3. Cytokine production test
염증반응은 과다한 면역반응으로 인한 염증성 사이토카인 증가로 유도되는데, 대표적인 cytokine으로는 TNF-α, IL-6, IL-1β, GM-CSF 가 있다. 대식세포에서 LPS에 의해 분비되는 pro-inflammatory cytokines 중 IL-6는 B cell을 형질세포로 분화시켜 항체 생산을 촉진하여 급성염증 반응을 만성 단계로 전환시키게 된다. 또한 TNF-α는 전신성 염증에 관여하는 cytokine으로, 대식세포 이외에도 NK cell이나 CD4 T 세포 에서서도 생산되는데 과량 생산시 발열, 세포사멸을 유도한다. IL-1β는 활성화된 대식세포에서 caspase-1을 활성화시켜 염증 반응의 주요 매개체로 작용하며, 특히 Th cell을 활성화시켜 과도한 염증 반응을 유도한다. Pro-inflammatory cytokines의 과량 분비 시 패혈증, 알츠하이머, 암, 염증성 장 질환 등의 다양한 질병의 요인이 된다.The inflammatory response is induced by an increase in inflammatory cytokines due to an excessive immune response, and representative cytokines include TNF-α, IL-6, IL-1β, and GM-CSF. Among the pro-inflammatory cytokines secreted by LPS in macrophages, IL-6 differentiates B cells into plasma cells, promotes antibody production, and converts an acute inflammatory response into a chronic phase. In addition, TNF-α is a cytokine involved in systemic inflammation. It is produced not only by macrophages but also by NK cells and CD4 T cells. Excessive production of TNF-α induces fever and apoptosis. IL-1β acts as a major mediator of inflammatory responses by activating caspase-1 in activated macrophages, and in particular induces excessive inflammatory responses by activating Th cells. Excessive secretion of pro-inflammatory cytokines is a factor in various diseases such as sepsis, Alzheimer's disease, cancer, and inflammatory bowel disease.
이에 아로니아 식초가 RAW 264.7 세포에서 LPS에 의해 유도된 염증성 cytokine에 미치는 영향을 확인하였다.Accordingly, the effect of aronia vinegar on inflammatory cytokines induced by LPS in RAW 264.7 cells was confirmed.
구체적으로, RAW264.7 세포를 24-well plate에 seeding 후, overnight 하였다. 이후 well에 LPS를 1μg/ml 농도, 시료를 농도별로 처리하여 24시간 CO₂ incubation 하였다. 그 다음 세포배양 상층액을 수거 하였다. 상층액에 포함된 cytokine인 IL-6, TNF-α, GM-CSF, IL-1β를 효소항체법 (enzyme-linked immunosorbent assay : ELISA)을 이용하여 측정 하였다. 즉, plate-bottom micro-well에 1차 항체 capture antibody를 coating buffer에 희석하여 100 μl/well로 분주하고 4℃에서 Overnight 후, washing 용액으로 세척하였다. 세척된 micro-well은 10% FBS가 첨가된 PBS로 blocking 하였으며, 실험에서 채취한 배양 상층액을 적당한 비율로 희석한 후 각 well에 분주하여 상온에서 반응시켰다. 그 다음, biotin이 부착된 2차 항체 100㎕/well와 일정시간 상온에서 반응시킨 후, enzyme reagent 100 μl/well을 첨가하였다. 마지막으로 기질을 첨가하여 발색시킨 다음 Microplate reader를 이용하여 측정하였다. 측정된 IL-6, TNF-α, GM-CSF, IL-1β의 농도는 표준곡선을 이용하여 환산하였다.Specifically, RAW264.7 cells were seeded in a 24-well plate and then overnight. Thereafter, LPS was added to the well at a concentration of 1 μg/ml, and the samples were treated for each concentration, followed by CO₂ incubation for 24 hours. Then, the cell culture supernatant was collected. The cytokines IL-6, TNF-α, GM-CSF, and IL-1β contained in the supernatant were measured using enzyme-linked immunosorbent assay (ELISA). That is, the primary antibody capture antibody was diluted in coating buffer in the plate-bottom micro-well, dispensed at 100 μl/well, overnight at 4° C., and washed with a washing solution. The washed micro-well was blocked with PBS supplemented with 10% FBS, and the culture supernatant collected in the experiment was diluted in an appropriate ratio and then dispensed into each well and reacted at room temperature. Then, after reacting with 100 μl/well of the biotin-attached secondary antibody at room temperature for a certain period of time, 100 μl/well of enzyme reagent was added. Finally, a substrate was added to develop color, and then the color was measured using a microplate reader. The measured concentrations of IL-6, TNF-α, GM-CSF, and IL-1β were converted using a standard curve.
그 결과 도 4에서 볼 수 있는 바와 같이, 아로니아 식초는 아로니아 식초 부산물에 비하여 cytokine 생성을 억제하였으며, 특히 IL-6 생성량에 현저한 영향이 있음을 확인하였다.As a result, as can be seen in Figure 4, it was confirmed that aronia vinegar inhibited cytokine production compared to aronia vinegar by-products, and in particular, had a significant effect on IL-6 production.
Claims (4)
상기 아로니아 식초는 아로니아 파쇄물을 제조하는 단계; 상기 아로니아 파쇄물에 배 농축액을 상기 아로니아 파쇄물의 총 중량 대비 2중량%로 첨가하는 단계; 상기 배 농축액이 첨가된 아로니아 파쇄물을 주정 70% 용매로 80 내지 100℃에서 2 내지 4시간 동안 추출하는 단계; 상기 아로니아 파쇄물의 주정 추출물을 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 및 사카로마이세스 불라디이(Saccharomyces boulardii)의 혼합 균주로 100 내지 130rpm으로 상온에서 70 내지 74시간 동안 알코올 발효하여 아로니아 와인을 제조하는 단계; 상기 아로니아 와인을 160 내지 170시간 동안 1일당 1시간씩 공기를 주입하면서 초산 발효하는 단계; 및 상기 초산 발효물을 원심분리하여 아로니아 식초인 상층액을 수득하는 단계;로부터 제조된 것을 특징으로 하는 항염증용 조성물.As an anti-inflammatory composition containing aronia vinegar,
The aronia vinegar is preparing an aronia lysate; Adding pear concentrate to the aronia lysate at 2% by weight based on the total weight of the aronia lysate; Extracting the aronia lysate to which the pear concentrate was added at 80 to 100 ° C. for 2 to 4 hours with 70% alcohol solvent; The alcohol extract of the aronia lysate was alcoholicly fermented at 100 to 130 rpm at room temperature for 70 to 74 hours with a mixed strain of Saccharomyces cerevisiae and Saccharomyces boulardii to obtain Aronia making wine; Fermenting the aronia wine with acetic acid while injecting air for 1 hour per day for 160 to 170 hours; And centrifuging the acetic acid fermentation product to obtain a supernatant of aronia vinegar; anti-inflammatory composition characterized in that produced from.
상기 아로니아 식초는 아로니아 파쇄물을 제조하는 단계; 상기 아로니아 파쇄물에 배 농축액을 상기 아로니아 파쇄물의 총 중량 대비 2중량%로 첨가하는 단계; 상기 배 농축액이 첨가된 아로니아 파쇄물을 주정 70% 용매로 80 내지 100℃에서 2 내지 4시간 동안 추출하는 단계; 상기 아로니아 파쇄물의 주정 추출물을 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 및 사카로마이세스 불라디이(Saccharomyces boulardii)의 혼합 균주로 100 내지 130rpm으로 상온에서 70 내지 74시간 동안 알코올 발효하여 아로니아 와인을 제조하는 단계; 상기 아로니아 와인을 160 내지 170시간 동안 1일당 1시간씩 공기를 주입하면서 초산 발효하는 단계; 및 상기 초산 발효물을 원심분리하여 아로니아 식초인 상층액을 수득하는 단계;로부터 제조된 것을 특징으로 하는 염증의 예방 및 개선용 식품 조성물.As a food composition for preventing and improving inflammation containing aronia vinegar,
The aronia vinegar is preparing an aronia lysate; Adding pear concentrate to the aronia lysate at 2% by weight based on the total weight of the aronia lysate; Extracting the aronia lysate to which the pear concentrate was added at 80 to 100 ° C. for 2 to 4 hours with 70% alcohol solvent; The alcohol extract of the aronia lysate was alcoholicly fermented at 100 to 130 rpm at room temperature for 70 to 74 hours with a mixed strain of Saccharomyces cerevisiae and Saccharomyces boulardii to obtain Aronia making wine; Fermenting the aronia wine with acetic acid while injecting air for 1 hour per day for 160 to 170 hours; And centrifuging the acetic acid fermentation product to obtain a supernatant, which is aronia vinegar. A food composition for preventing and improving inflammation, characterized in that produced from.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210002222A KR102557702B1 (en) | 2021-01-07 | 2021-01-07 | Composition for anti-inflammation comprising Aronia vinegar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210002222A KR102557702B1 (en) | 2021-01-07 | 2021-01-07 | Composition for anti-inflammation comprising Aronia vinegar |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220099855A KR20220099855A (en) | 2022-07-14 |
KR102557702B1 true KR102557702B1 (en) | 2023-07-20 |
Family
ID=82406858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210002222A KR102557702B1 (en) | 2021-01-07 | 2021-01-07 | Composition for anti-inflammation comprising Aronia vinegar |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102557702B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160082162A (en) * | 2014-12-31 | 2016-07-08 | 재단법인 베리앤바이오식품연구소 | Method for Venegar Using Aronia and Venegar Beverage Using Thereof |
KR20170058728A (en) * | 2015-11-19 | 2017-05-29 | 건양대학교산학협력단 | Manufacturing method of functional fermented vinegar beverage with chokeberry extract |
KR102330845B1 (en) * | 2019-06-03 | 2021-11-25 | 재단법인 순천바이오헬스케어연구센터 | A composition for antioxiation and antiinflammation comprising aronia fermented broth and Reed young leave extract |
-
2021
- 2021-01-07 KR KR1020210002222A patent/KR102557702B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20220099855A (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109718255B (en) | Preparation method of hangover relieving enzyme powder and hangover relieving composition containing the same | |
KR101705548B1 (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
KR102478724B1 (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
KR20220025679A (en) | Method for producing fermented apple postbiotics with increased effective component content using lactic acid bacteria | |
KR101976260B1 (en) | Method of Preparing Red-Ginseng Vinegar | |
KR20220025680A (en) | Method for producing fermented balloon flower postbiotics with increased effective component content using lactic acid bacteria | |
KR101690779B1 (en) | A method for manufacturing fermented composition comprising red gingseng and rubus coreanus and the fermented composition by the method | |
KR101236233B1 (en) | Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing the extract of Youngia denticulata, fraction of thereof or compound isolated therefrom as an active ingredient | |
KR102350102B1 (en) | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component | |
KR20220099856A (en) | Aronia vinegar beverage composition and manufacturing method thereof | |
KR20210100802A (en) | Method for producing fermented spinach and fermented soybean with increased effective component content using lactic acid bacteria | |
KR102557702B1 (en) | Composition for anti-inflammation comprising Aronia vinegar | |
KR102537844B1 (en) | Composition with antibacterial, antioxidant, and anti-inflammatory activity containing ingredients converted to kimchi lactic acid bacteria and breast lactic acid bacteria in marigold extract | |
KR101494664B1 (en) | fermented corni fructus composition with antioxidant activity and method of making the same | |
KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
KR102080720B1 (en) | Composition for enhancing immune function containing a fermented soybean | |
KR20220025681A (en) | Method for producing fermented cranberry postbiotics with increased effective component content using lactic acid bacteria | |
KR101891408B1 (en) | A composition comprising ganoderma lucidum grown on hulled barley extracts having anti-oxidation or anti-inflammation activity | |
KR102339984B1 (en) | An Antibacterial and Antioxidant Composition using Scenedesmus intermedius Extract | |
KR20220054023A (en) | A composition for immune enhancement comprising benicasa hispida extract | |
KR101970320B1 (en) | Composition for preventing, improving or treating respiratory diseases comprising fermented solution of Chaenomeles sinensis as effective component and production method thereof | |
KR20110092482A (en) | Improvemnet of anti-inflammatory activity of hibiscus cannabbinus extract by far infrared ray drying process | |
KR101791830B1 (en) | The compositions of anticancer effect of women cancers comprising wheat germ extract and preparation method thereof | |
KR102597975B1 (en) | FUNCTIONAL BEVERAGE FOR CHILDREN COMPRISING Phellinus linteus EXTRACT IMPROVED ANTIOXIDANT ACTIVITY AND METHOD FOR PREPARING THE SAME | |
KR102671827B1 (en) | Health functional food composition with excellent nitric oxide production inhibition effect containing quercetin as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |